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Abstract 
Hemoglobinopathies such as sickle cell anemia and thalassemias are the most 
common inherited single-gene disorders in the world. They cause substantial 
morbidity and represent a major health burden worldwide. Molecular pathology of 
these diseases is well studied in which they are caused by the inheritance of defective 
globin genes that would result in defective adult hemoglobin in the patients and thus, 
clinical condition since their childhood. Classic treatment methods are blood 
transfusion and bone marrow transplantation, however, weaknesses were reported for 
both strategies and this impel the development of new treatment method. In most of 
these patients, their upstream y-globin genes that are switched off during 
developmental stage remain intact and are fully functional. Reactivation of these 
genes can moderate the severity of the disease by substituting y-globin for defective 
P-globin to resume functional hemoglobin synthesis. Pharmacological agents aimed 
for y-globin gene reactivation were discovered. Nevertheless, considerable toxicity 
and ineffectiveness of these drugs limited their role in long-term treatment. In year 
2003, a lead compound LC978, which is competent in reactivating gamma-globin 
genes, was discovered and purified from a traditional Chinese medicine (TCM) in Dr. 
Fung's laboratory. In vitro pharmacological assessment of LC978 showed significant 
efficacy on inducing hemoglobin expression in human myelogenous leukemia K562 
model cell line, normal human erythroid progenitor cells and erythroid progenitor 
cells sampled from beta-thalassemia patient. The efficacy of LC978 on inducing 
hemoglobin expression is 2000-fold more potent than hydroxyurea, a drug currently 
used in bringing up hemoglobin expression. Besides, LC978 excels hydroxyurea in 
having an optimal dosage distant from its cytotoxic dosage. These results suggested 
the feasibility of LC978 as a drug candidate in improving current clinical scenario of 
hemoglobinopathies. In order to proceed with the development of this drug, its 
vii 
mechanism in inducing hemoglobin expression is to be unveiled. It is believed that 
transcriptional regulation of gamma globin gene was involved in LC978-induced 
fetal hemoglobin production, experiments to elucidate the promoter regulation upon 
LC978 induction was performed. In this study, promoter-reporter constructs driven 
by human y-globin gene -1224, -754 and -205 promoter were built to drive 
expression of secreted alkaline phosphatase (SEAP) reporter gene, and their 
responses towards LC978 induction were investigated. From the results, it was found 
that promoter-reporter constructs without locus control region (LCR) were shown not 
inducible by LC978 and hydroxyurea, but inducible by sodium butyrate. It was 
believed that LC978 may not possess histone deacetylase inhibition activity, and that 
its induction profile determined in this study was similar to that of hydroxyurea. It 
was assumed that LC978 possesses specific gamma globin gene induction through an 
LCR-dependent mechanism. Directions of further study could be mapping the 
LC978-responsive elements on LCR and investigating the subset of transcription 













年，一種命名爲L C 9 7 8的先導性化合物在瑪教授的實驗室內從傳統中草藥 
中被發現並提取出來，此化合物能有效的激活Y珠蛋白基因。試管藥理學之檢 
測顯示，L C 9 7 8能有效地在人類骨髓性白血病K 562細胞株內、正常人 
類血紅系始祖細胞內及P型地中海貧血症病人之血紅系始祖細胞內誘導血紅蛋 
白的表達，並且比經基脲，一種普遍採用於提高血紅蛋白之表達的藥物高出二 
千倍的效能。除此之外，L C 9 7 8因其最優劑量遠低於其細胞抑制的劑量而 
比經基脲更爲優勝。這些結果表示了L C 9 7 8作爲改善血紅蛋白病變臨床症 
狀之侯選藥物的可能性。爲了這種藥物的發展，我們必須探討L C 9 7 8在誘 
導血紅蛋白之表達中所採取的機制。我們相信L C 9 7 8所誘導之胎兒血紅蛋 
白之表達牽涉Y珠蛋白基因的轉錄調控，因而進行了一系列的實驗來闡明L C 
9 7 8所誘導之啓動子調控。我們建構了連接人類Y珠蛋白基因—12 2 4 � 
一 7 5 4 及 一 2 0 5啓動子及報導基因的質體載體去驅動分泌性驗性磷酸酶報 
導基因，並檢測它們在L C 9 7 8誘導下的反應。硏究結果顯示，這些不具有 
基因點控制區的質體載體並不能被L C 9 7 8及經基脲誘導，但能被丁酸鈉所 
ix 
誘導。我們相信L C 9 7 8可能不具有抑制組織蛋白去乙醢基酶的特性，同時’ 
硏究結果亦指出L C 9 7 8的誘導槪形跟經基脲相似。我們認爲L C 9 7 8是 
通過一種依賴基因點控制區的機制去準確誘導人類T珠蛋白基因。未來的硏究 
方向可以置於勘測位於基因點控制區內的L C 9 7 8反應元素及調查L C 9 7 
8所誘導出的轉錄因子方面。 
XV 
Table of Contents 
Title i 




Abstract (English) vii 
Abstract (Chinese) ix 
Table of contents xi 
List of Figures xvi 
Chapter 1: General Introduction 1 
1.1 Human Hemoglobin 1 
1.2 Hemoglobinopathies 4 
1.3 Hereditary Persistence of Fetal Hemoglobin (HPFH) and 6 
P-Thalassemias 
1.4 Globin Genes Switching 7 
1.5 Pharmaceutical Agents for y-Globin Gene Reactivation 9 
1.6 Discovery of LC978: A Novel Fetal Hemoglobin Inducing Agent 10 
1.7 Aim of Study 11 
Chapter 2: Specific Induction of Gamma Globin Gene 12 
Transcription in K562 Leukemia Cell Line by 
Lead Compound LC978 
2.1 K562 Cell Line as a Model for Gamma Globin Gene Induction 12 
Studies 
2.2 LC978-Induced Fetal Hemoglobin Expression in K562 Cell Line 12 
2.3 Materials 14 
2.3.1 Chemicals, Kits and Reagents 14 
2.3.2 Buffers and Solutions 15 
2.3.3 Cell Line 16 
2.3.4 Instruments and Equipments 16 
2.3.5 Enzymes 16 
2.3.6 Nucleic Acids 17 
2.3.7 Oligo Primers 17 
2.4 Methods 17 
2.4.1 In vitro Bioassay for Total Hemoglobin Production 17 
(a) Preparation of Treatment Cell Culture Plates 17 
xi 
(b) Treatment of K562 Cells by LC978 18 
(c) Signal Development 18 
2.4.2 Detection of Fetal Hemoglobin Production by HbF Sandwich 18 
ELISA 
(a) Treatment of K562 Cells by LC978 18 
(b) Preparation of Capture Antibody-Coated and BSA-Blocked 19 
ELISA Plate 
(c) Preparation of K562 Cell Lysates 19 
(d) Antigen Capture and Signal Development 19 
2.4.3 Detection of Gamma Globin mRNA Level by Real-time RT-PCR 20 
(a) Treatment of K562 Cells by LC978 20 
(b) Preparation of K562 Cell Lysate in Guanidium Thiocyanate 20 
(GT) Solution 
(c) Isolation of Total RNA from LC978-treated K562 Cells 21 
(d) cDNA Synthesis from mRNA by Reverse Transcriptase (RT) 22 
(e) Real-Time Quantitative Polymerase Chain Reaction (PCR) 23 
2.5 Results 24 
(a) In vitro Bioassay for Total Hemoglobin Production 24 
(b) Fetal Hemoglobin Sandwich ELISA 24 
(c) LC978-Induced Gamma Globin mRNA Accumulation 25 
2.6 Discussion 31 
Chapter 3: Construction of Promoter-Reporter Plasmid 33 
Constructs 
3.1 The Human Gamma Globin Gene Promoter 33 
3.2 SEAP as a Reporter Gene for Promoter Deletion Study 34 
3.3 Materials 35 
3.3.1 Chemicals, Kits and Reagents 35 
3.3.2 Buffers and Solutions 35 
3.3.3 Bacterial Strain 36 
3.3.4 Cell Line 36 
3.3.5 Enzymes 37 
3.3.6 Nucleic Acids 37 
3.3.7 Oligo Primers 37 
3.4 Methods 38 
3.4.1 Molecular Cloning of A-Gamma Globin Gene Promoter and 3’ 38 
Enhancer into pBlueScript II SK (-) . 
(a) Design and Synthesis of Oligo Primers 38 
xii 
(b) Isolation of Genomic DNA from K562 Cells 39 
(c) PGR Amplification of Gamma Globin Gene Promoter and 3， 40 
Enhancer 
(d) Ligation of PGR Fragments into EcoR V-cut pBlueScript II SK 41 
(-) 
(e) Preparation of E. coli DH5a Competent Cells 43 
(f) Heat-Shock Transformation of E. coli DH5a Competent Cells 44 
(g) PGR Screening and Plasmid Purification of Putative 44 
pBlu2SKM-yAP and pBlulSKM-yAE 
(h) Isolation of Putative pBlu2SKM-yAP and pBlu2SKM-YAE 45 
Plasmid DNA 
(i) Nucleotide Sequencing of Putative pBlu2SKM-yAP and 47 
PB1U2SKM-YAE 
(j) Graphical Summary of Section 3.6.1 Sub-cloning Procedures 49 
3.4.2 Molecular Cloning of A-Gamma Globin Gene Promoter and 3' 51 
Enhancer into pSEAP2-Enhancer 
(a) Sub-cloning of Promoter Fragment into pSEAP2-Enhancer 51 
(b) Sub-cloning of 3，Enhancer Fragment into p 1224yAP-SEAP2 52 
(c) Graphical Summary of Section 3.6.2 Sub-cloning Procedures 54 
3.4.3 Construction of p 1224yAP-SEAP2-YAE Promoter Deletions 56 
Constructs 
(a) Restriction Digestion at 5' End of A-Gamma Promoter Deletions 56 
(b) Restriction Digestion at 3' Ends of A-Gamma Promoter 56 
Deletions 
(c) Blunting 5'-overhangs and Self-Ligation of Linearized Plasmid 57 
Constructs 
(d) Graphical Summary of Section 3.6.3 5’ Deletions Procedures 58 
3.5 Results 59 
(a) Nucleotide Sequence Confirmed by Cycle Sequencing 60 
(b) Resulting Plasmid Constructs p 1224yAP-SEAP2-yAE, 64 
p754yAP-SEAP2-yAE and p205yAP-SEAP2-yAE 
3.6 Discussion 67 
Chapter 4: Mapping of LC978-Responsive Elements on 69 
Human A-Gamma Globin Gene Promoter 
4.1 Introduction 69 
4.2 pSV-p-Galactosidase as a Transfection Normalization Standard 69 
4.3 pSV-p-Galactosidase as a Transfection Normalization Standard 70 
xiii 
4.4 Materials 72 
4.4.1 Chemicals, Kits and Reagents 72 
4.4.2 Buffers and Solutions 73 
4.4.3 Cell Line 74 
4.4.4 Nucleic Acids 74 
4.4.5 Instruments and Equipments 74 
4.5 Methods 74 
4.5.1 Determination of Optimal Dose of Transfection Reagent for 74 
K562 
(a) Sterilization of Plasmid DNA for Transfection 74 
(b) Transient Transfection of K562 Cells by pEGFP-N 1 75 
(c) Examination of EGFP Expression Level 76 
4.5.2 p-Galactosidase as Normalization Standard for K562 76 
Transfections 
(a) Transient Transfection of K562 Cells by pSV-P-Gal 76 
(b) Determination of p-Galactosidase Expression Level 76 
4.5.3 Mapping of LC978-Responsive Elements on Human Gamma 77 
Globin Gene Promoter 
(a) Co-Transfection of K562 Cells by p 1224/754/205yAP-SEAP2 77 
-yAE and pSV-|3-Gal 
(b) Treatment of Co-Transfected K562 Cells by LC978 77 
(c) Determination of P-Galactosidase Expression Level 78 
(d) Determination of Secreted Alkaline Phosphatase (SEAP) 78 
Expression Level 
(e) Determination of Fetal Hemoglobin Expression Level 79 
4.5.4 Mapping of Hydroxyurea-Responsive Elements on Human 80 
Gammm Globin Gene Promoter 
(a) Determination of Optimal Biological Dose (OBD) of 80 
Hydroxyurea 
(b) Co-Transfection of K562 Cells and Subsequent Treatment by 80 
Hydroxyurea 
(c) Assay for p-Galactosidase (P-Gal), Secreted Alkaline 81 
Phosphatase (SEAP) and Fetal Hemoglobin (HbF) Expression 
Level 
4.5.5 Sodium Butyrate-Induced SEAP Expression 81 
(a) Determination of Optimal Biological Dose (OB(d) of Sodium 81 
Butyrate 
(b) Co-Transfection of K562 Cells and Treatment by Sodium 82 
xiv 
Butyrate 
(c) Assay for p-Galactosidase (P-Gal), Secreted Alkaline 83 
Phosphatase (SEAP) and Fetal Hemoglobin (HbF) Expression 
Level 
4.5.6 Data Analysis 83 
(a) Data Processing, Normalization and Graphing 83 
(b) Statistical Analysis 83 
4.6 Results 84 
4.6.1 Optimal Dose of Transfection Reagent for K562 84 
4.6.2 P-Galactosidase as Normalization Standard for K562 84 
Transfections 
4.6.3 LC978 Induction on Co-Transfected K562 Cells 84 
4.6.4 Hydroxyurea Induction on Co-Transfected K562 Cells 85 
4.6.5 Sodium Butyrate Induction on Co-Transfected K562 Cells 86 
4.7 Discussion 98 
4.7.1 Theme Question to be Answered 98 
4.7.2 Optimal Dose ofDMRIE-C Transfection Reagent on K562 Cell 98 
Line 
4.7.3 pSV-P-gal as an Internal Normalization Control 99 
4.7.4 Responsive Element Mapping 99 
(a) LC978-Induced Response 100 
(b) Hydroxyurea-Induced Response 100 
(c) Sodium Butyrate-Induced Response 101 
4.7.5 LCR-Dependent Gamma Globin Gene Reactivation 101 
4.7.6 Induction of Gamma Globin by Histone Deacetylase Inhibitor 104 
4.7.7 Basal SEAP Expression Levels of the Promoter-Reporter 105 
Constructs 
4.7.8 Summary 105 
Chapter 5: General Discussion 106 
References Cited 109 
XV 
List of Figures 
Figure Title Page 
1.1 Developmental Regulation of Globin Genes. 3 
2.1 Total Hemoglobin Production Induced by LC978，a Response vs. 26 
Concentration Perspective. 
2.2 Total Hemoglobin Production Induced by LC978, a Response vs. 27 
Time Perspective. 
2.3 Total Hemoglobin Production Induced by LC978, a Response vs. 28 
Time Perspective at Different Concentrations. 
2.4 Fetal Hemoglobin Production Induced by LC978 over a 7-Day Period. 29 
2.5 GAPDH-Normalized Expression Level of Gamma Globin. 30 
3.1 Schematic Diagram of Self-made Centrifugal-filtration Apparatus. 42 
3 2 Molecular Cloning of Human A Gamma Globin Gene Promoter. 49 
3.3 Molecular Cloning of Human A Gamma Globin Gene 3 ’ Enhancer. 5 0 
3.4 Sub-Cloning of Human A Gamma Globin Gene Promoter into 54 
pSEAP2-Enhancer. 
3.5 Sub-Cloning of Human A Gamma Globin Gene 3’ Enhancer into 55 
p 1224yAP-SEAP2-Enhancer. 
3.6 Generation of 5' Deletions in Human A Gamma Globin Gene 58 
Promoter in p 1224YAP-SEAP2-yAE. 
3.7 Sequence Flanked by MFll84/MFl 185 in pl224yAP-SEAP2-YAE. 60 
3.8 Sequence Flanked by MF1186/MF1187 in pl224YAP-SEAP2-yAE. 61 
3.9 Sequence Flanked by MFl l 84/MFl 185 in p754yAP-SEAP2-yAE. 62 
3.10 Sequence Flanked by MFll84/MF1185 in p205YAP-SEAP2-yAE. 63 
3.11 Schematic Diagram of p 1224YAP-SEAP2-yAE. 64 
3.12 Schematic Diagram of p754YAP-SEAP2-yAE. 65 
3.13 Schematic Diagram of p205yAP-SEAP2-yAE. 66 
4.1 Optimal Dose of DMRIE-C Reagent for K562 Transfection. 88 
4.2 pSV-p-gal Transfection and p-Galactosidase Assay on K562 Cells. 89 
4.3 HbF Production by Dual-Vector Co-Transfected K562 Cells Upon 90 
LC978 Treatment. 
4.4 SEAP Expression by Dual-Vector Co-Transfected K562 Cells Upon 91 
LC978 Treatment. 
4.5 Total Hemoglobin Production Induced by Hydroxyurea over a 8-Day 92 
Period. 
4.6 HbF Production by Dual-Vector Co-Transfected K562 Cells Upon 93 
Hydroxyurea Treatment. 
xvi 
4.7 SEAP Expression by Dual-Vector Co-Transfected K562 Cells Upon 94 
Hydroxyurea Treatment. 
4.8 Fetal Hemoglobin Production Induced by Sodium Butyrate over a 95 
6-Day Period. 
4.9 HbF Production by Dual-Vector Co-Transfected K562 Cells Upon 96 
Sodium Butyrate Treatment. 
4.10 SEAP Expression by Dual-Vector Co-Transfected K562 Cells Upon 97 
Sodium Butyrate Treatment. 
xvii 
Chapter 1 General Introduction 
1.1 Human Hemoglobin 
Hemoglobin (Hb) of human is a tetrameric metalloprotein (Ingram, 1956). In fact, 
the name hemoglobin is the concatenation of heme and globin, implying that the 
molecule is actually an assembly of globular protein and heme group. The assembly 
of human hemoglobin consists of four globular protein subunits in which two are 
a-like chains and two are p-like chains (Ingram, 1956). These globin chains tightly 
associate themselves into a quaternary conformation by salt bridges, hydrogen bonds 
and hydrophobic interactions to encompass a non-protein heme group (Fung and Ho, 
1975; Ackers, 1980; Shaanan, 1983). This iron-containing heme group contributes to 
reversible binding of oxygen by hemoglobin, enabling it to serve a vital role as an 
oxygen transporter in human body. Hemoglobin is carried by red cells to take up 
life-supporting oxygen from lungs and release in the rest of the body, and in a reverse 
way transport metabolic waste carbon dioxide back to the lungs. Functional 
hemoglobin is therefore a vital component of human being. 
The genes that encode for a-like and p-like globin chains are located within human 
chromosome 16 and 11 respectively (Figure 1.1 A). The (3-like globin genes cluster 
spans 60kb at short arm of chromosome 11, contains five functional genes (s, Gy, Ay, 
5, P) and one pseudo gene (\|/p), in which a region named locus control region (LCR) 
located 6kb to 20kb upstream to 8-globin gene acts as cw-acting element in 
developmental regulation of downstream P-globin genes switching through a looping 
mechanism (Li et aL, 2002). The a-like globin genes cluster locates at short arm of 
chromosome 16 with a size of 30kb. The locus contains three functional genes (;，al, 
a2) and three pseudo genes (\}/(’ y a l , \\fa2). A DNase I hypersensitive site (HS40) 
was identified at 40kb 5' upstream to ^-globin gene, in which it has been 
1 
characterized to be functionally similar to LCR in P-globin genes cluster (Jarman et 
al., 1991). 0 gene was recently identified to be an a-like globin gene (Hsu et aL, 
1988). Though sequence analysis showed that the gene contains all structural features 
that are necessary for expression, the amino-acid structural prediction of the protein 
product suggests that the 0-globin is unlikely functional (Clegg, 1987). In fact, 
9-globin mRNA transcript was found to present at very low level which accounts for 
less than 1% of a-globin chain, and no hemoglobin containing the 9-globin chain has 
ever been identified (Albitar et al., 1989). 
Several copies of a-like and p-like globin genes present in each of the loci, and they 
are developmentally regulated known as globin gene switching, which is a classic 
example of ordered regulation of gene expression in development (Nienhuis & 
Stamatoyannopoulos, 1978). Throughout developmental phases, the predominate 
population of hemoglobin produced and circulated within the body as well as the 
major site of erythropoiesis change over time (Figure I.IB). During the embryonic 
, development starting from the third to eighth weeks of gestation, major 
erythropoietic site occurs at the yolk sac, where embryonic hemoglobins are 
produced. At this stage, a-like a and ^ globins as well as (3-like y and 8 globins are 
expressed. They combine with each other to form Hb Gower 1 (^82), Hb Gower 2 
(a2S2) and Hb Portland (C2Y2). Starting from the fifth week of gestation, major 
erythropoietic site begins to move from yolk sac to the fetal liver, which is 
accompanied by a gradual reduction in expression of the two transitory ^ and s 
globins. Fetal hemoglobin HbF (ajyi) begins to synthesize and become the 
predominant hemoglobin produced throughout the fetus life, p globin chain was 
found to express at early stage of gestation, while its synthesis becomes significant 
near the time of birth. Upon birth, there is a significant shift of hemoglobin synthesis 
from fetal hemoglobin to adult hemoglobin HbA (a2p2), and a shift of erythropoietic 
2 
site from liver to bone marrow as well. At the age of three months, HbA 
predominates and accounts for over 95% of total hemoglobin present in the body and 
this persists throughout the life span. Though another P-like 6 globin begins to 
express since late fetal life, HbA: (a252) never accounts for more than 2% of adult 
hemoglobin. 
HS40 C v|/C\|/al v|/a2 a2 al 9 
] _ D O H I l i S O " 
Human a-globin cluster HBA at chromosome 16pl3.3 
8 Gy Ay \|/P P 
I LCR h i 
Human P-globin cluster HBB at chromosome l lpl5.5 ^ 
Yolk sac Liver Spleen Bone marrow 
. I 
I 乂 
0 1 1 1 7 1 1 1 1 
0 6 18 30 ‘ 6 18 30 42 
Prenatal age (weeks) Postnatal age (weeks) 
Birth 
B 
Figure 1.1 Developmental Regulation of Globin Genes. (A) The globin gene 
clusters on chromosome 16 and 11. LCR, locus control region. 
Functional globin genes were designated by shaded boxes, while 
non-functional or pseudo genes were designated by open boxes. 
(Grosveld et a I., 1993) (B) At embryonic, fetal and adult stage during 
development, different globin genes are activated and different globin 
chains are synthesized. They associate with each other to form different 
hemoglobins at corresponding site of erythropoiesis. (Adopted from 
Hoffbrand, Pettit and Moss, 2001, Essential Hematology Edition. 
Blackwell Science, UK. p. 72) 
3 
1.2 Hemoglobinopathies 
Functional hemoglobin is of vital importance to human being, and disorders of 
hemoglobins lead to clinical consequences termed hemoglobinopathy. Hemoglobin 
abnormalities are the result of sequence alternation of globin peptides or reduced rate 
of globin synthesis, in which both are the outcomes of defective globin genes. 
Structural variants of hemoglobin involve peptide chain alternations in a- or 
(3-globins which arises mostly from single nucleotide substitution that produce 
missense mutation (Kazazian, 1990). Variants may also arise from premature 
translational stop or peptide elongation due to mutation at stop codon (Orkin, 1987). 
There are also fusion variants of hemoglobin that result from homologous 
recombination of globin genes (Baglioni, 1962). Structural variants of hemoglobin 
may exhibit unstable physical properties including altered oxygen affinity or 
abnormally rigid structure. The former property may affect the capability of 
hemoglobin as an oxygen transporter as reversible oxygenation is altered. The latter 
property may lead to serious clinical feature such as hemolytic anemia. Sickle cell 
disorder is the first and best characterized single gene disorder (Pauling et al., 1949) 
that involves a single nucleotide substitution at p-globin gene to give rise of valine 
for glutamic acid substitution at the sixth amino acid of the P-globin polypeptide 
chain (Ingram, 1956; Ingram, 1959). The hemoglobin that harbors this abnormal 
globin chain is named sickle cell hemoglobin (HbS), in which it possesses abnormal 
physical property. Under low oxygen tension, HbS aggregates into rod shaped 
polymers and distort the shape of erythrocyte to sickle shape, which may lead to 
severe hemolytic condition (Smits et al., 1969). 
Thalassemias are the most common human single gene disorders that result from 
reduced rate of globin chain synthesis due to mutations in globin genes (Weatherall 
& Clegg, 2001). For instance, p-thalassemias describe decreased p-globin syntheses 
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due to impaired P-globin gene expression, which in turn lead to accumulation of 
excessive a-globin chains and cause damage to red cell membrane (Schrier, 2002). 
p-thalassemias are mainly caused by single base substitution in the p-globin gene, 
including promoter mutants, mutation at RNA splicing sites, nonsense mutation that 
gives premature stop codon or single base deletion to give frameshift mutations 
(Bunn et al., 1977). Altogether these mutants have impaired P-globin expression or 
expression of defective P-globin mRNA transcripts, which in turn lead to reduced 
rate of p-globin synthesis. Individuals who carry single copy of P-thalassemia allele 
are clinically benign, and they are said to have thalassemia minor. Carriers of 
homozygous P-thalassemia alleles are said to have thalassemia major, in which their 
clinical severity varies depending on the two alleles they present. The onset of 
P-thalassemia begins at postnatal period when developmental switch of y- to P-globin 
gene takes place, p-thalassemia major affects mostly young patients, as their survival 
to the adulthood is rare. These patients suffer not only from clinical outcomes such as 
hemolytic anemia and dyserythropoiesis, but also from lifelong medical treatment 
such as blood transfusion and iron chelating therapy that greatly impairs their quality 
of life. 
Hemoglobinopathy and p-thalassemias are not rare, and in fact they show a global 
epidemic prevalence. In a recent study, Weatherall and Clegg censused the global 
distribution of hemoglobin disorders (Weatherall & Clegg, 2001). It was estimated 
that annually there may be about 270 million carriers for important inherited 
hemoglobin disorders and 300,000 - 400,000 births of infants with sickle-cell 
anaemia or serious forms of thalassaemia, with South-East Asia being the most 
severely affected. Regional carrier frequencies of P-thalassemia range from 2-18% in 
Eastern Mediterranean, 0-19% in Europe, 0-13% in Western Pacific and 0-11% in 
Southeast Asia. It is also estimated that from year 2005 to 2025, 20,000 
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p-thalassemia homozygotes will be bom each year in southern provinces of China. 
Concluding these all, hemoglobinopathies and p-thalassemias are of significant 
importance on global health issue and they create international health burden 
(Weatherall & Clegg, 2001). 
1.3 Hereditary Persistence of Fetal Hemoglobin (HPFH) and ^-Thalassemias 
In normal development, fetal y-globin genes are switched off and P-globin gene 
becomes active during neonatal period. In fact, some people may exhibit impaired 
perinatal switch from y- to p-globin synthesis and continue to synthesize fetal 
hemoglobin that persist their adulthood. The cause of HPFH is multifold, either 
mutations in regulatory sequence of y-globin gene promoters, mutations in globin 
genes, tram-aciing factors or deletions of whole 6- and P-globin genes can result in 
HPFH (Poncz et al., 1989). HPFH is related to P-thalassemias in a way that it 
provides insight on therapy of P-thalassemias. In 1975, Charache et al. reported a 
case study performed on a 15-year-old Negro male, who was the world first reported 
case of homozygous HPFH carrier (Charache et al., 1975). Analysis showed that the 
blood of the subject contained no HbA or HbA� but only HbF, while interestingly 
only mild clinical disorder was observed, which was due to slight thalassemia trait 
from imbalance of a- to y-globin synthesis ratio. The finding evidenced that HPFH, 
or postnatal expression of y-globin and synthesis of HbF can ameliorate 6- and 
p-thalassemias. Though most homozygous P-thalassemia patients suffer from clinical 
outcomes and complications, this report suggested that individual with complete 
absence of HbA and HbA: can survive with mild clinical features with compensation 
from HbF. By then, reactivation of the developmentally switched off y-globin gene in 
adulthood became a potential therapeutic measure to p-thalassemias and related 
studies blossomed in the past few decades (Rodgers and Saunthararajah, 2001). 
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1.4 Globin Genes Switching 
As described before, the P-globin genes cluster at chromosome 16 and are precisely 
regulated throughout developmental stages. Through extensive studies during the last 
30 years, a considerable understanding of cellular and molecular control of 
hemoglobin switching has been accumulated. In early years in 1970s, it was 
hypothesized that hemoglobin switching was due to clonal successions of two stem 
cell lineages that have discrete globin gene expression programs: a fetal stem cell 
lineage committed to fetal globin expression is replaced at perinatal period by an 
adult stem cell lineage committed to adult hemoglobin expression (Weatherall et al, 
1976). This hypothesis was raised after immunochemical staining revealed that a 
fetal hemoglobin-containing cell population called F cells was found in all adults, 
and that the HbF is cellularly restricted (Boyer et al., 1975; Wood et al, 1975). 
However, others argued that hemoglobin switching takes place in single cell lineage 
via changes in gene expression programme (Papayannopoulou et al., 1977). 
Subsequent experiments settled the argument. One study showed that in vitro 
cultured erythroid burst forming units (BFUe) colony derived from adult erythroid 
cells produced abundant fetal hemoglobin (Papayannopoulou et al., 1976). However, 
these colonies, instead of segregating into HbF expressing colonies and HbA 
expression colonies, the research group found that most colonies contained both cells 
that produce either HbF or HbA (Papayannopoulou et cd., 1977). This suggested that 
hemoglobin switching takes place in the same cell lineage, where switching occurs 
via cell differentiation accompanied by a change in transcriptional environment 
(Papayannopoulou et al； 1977). It has been postulated that hemoglobin switching is 
in some way linked to differentiative events, in which a switch of globin gene 
transcription programme from one that allow y-globin expresson to one that support 
p-globin expression takes place as differentiation advances (Papayannopoulou et al., 
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1977; Stamatoyannopoulos, 1979). In fact experimental results supported the 
hypothesis. Baboons were treated with high dose of erythropoietin to accelerate 
erythropoiesis, the outcome, was as expected, that an increased fetal hemoglobin 
synthesis was accompanied (Al-Khatti et al., 1987; Umemura, 1988). This could be 
explained by rapid regeneration of erythroid stem cells, which gave rise to premature 
terminally differentiated cells that still possess primitive fetal globin gene expression 
programme (Stamatoyannopoulos et al., 1985). 
How are the globin genes regulated at molecular level? This question has long been 
asked in the past twenty years, and efforts put in the past twenty years have helped 
elucidating the underlying mechanism. In 1980s, a region located upstream to 
8-globin genes was found to contain a series of DNase I hypersensitive sites, which 
was shown to have regulatory relevance to the downstream globin genes. Subsequent 
studies showed that the region, termed locus control region (LCR), was of 
fundamental importance to developmental control of globin genes (Grosveld et al., 
1987). It is now generally accepted that the LCR controls the downstream globin 
genes via a flip-flop looping mechanism where the transcriptional apparatus on LCR 
come to proximity of the globin genes to interact with proximal regulatory elements, 
dependent on the stage of development (Wijgerde et al., 1995). The looping model 
suggests that each of downstream globin genes competes for the LCR, and that only 
one globin gene is expressed at a time. Details governing the molecular mechanism 
of globin gene switching remains to be elucidated and attracted focus from 
worldwide research groups. 
8 
1.5 Pharmaceutical Agents for y-Globin Gene Reactivation 
Since the introduction of cellular control of hemoglobin switching, pharmaceutical 
agents that were targeted at bringing up fetal hemoglobin expression were discovered. 
Early inducing agents reported were cytotoxic drugs that were targeted at inducing 
rapid regeneration of erythroid stem cells to produce an increased population of 
premature terminally differentiated F cells. For instance, in vivo and in vitro 
experiments showed that 5-azacitidine, a cytotoxic drug, was capable in inducing 
HbF production by triggering secondary erythroid regeneration (DeSimone et al., 
1982; Ley et al., 1982). Later on, another cytotoxic drug hydroxyurea was also tested 
and proved for its HbF inducing ability in experimental animals (Letvin et al., 1984) 
and human (Piatt et al., 1984; Veith et al.，1985; Dover et al., 1986; Charache et al., 
1987). Following these studies, hydroxyurea later on became the first and only drug 
approved by the Food and Drug Administration (FDA) for the treatment of 
hemoglobinopathies (Atweh & Loukopoulos, 2001). However, considerable 
cytotoxicity and side-effects have limited its role in long term treatment (Halsey & 
Roberts, 2003). 
The observation of delayed y- to p-globin gene switching in infants of diabetic 
mothers has led to discovery of another class of HbF inducers (Perrine et al., 1985). 
It was postulated that the metabolite presents in these diabetic mothers contributed to 
the phenomenon. The metabolite was then identified to be a short chain fatty acid 
y-aminobutyric acid (Perrine et al., 1987). Subsequent studies found that derivatives 
of butyrate were capable of inducing HbF production in vivo (Perrine et al., 1989; 
Constantoulakis et al., 1991). The mechanism of reactivation of y-globin gene by 
butyrate was hypothesized to be through inhibition of histone deacetylase 
(Gabbianelli et al., 2000). It was believed that histone acetylation weakens the 
binding of histone to nucleosomal DNA, which in turn give rise to open chromatin 
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structure that become easily accessible to transcription factors (Vettese-Dadey et al., 
1996). However, administration of butyrate and its derivatives to sickle cell anemia 
and p-thalassemias patients still remains experimental, and no clinical use is 
permitted. 
1.6 Discovery of LC978: A Novel Fetal Hemoglobin Inducing Agent 
In year 2003, a lead compound extracted and purified from traditional Chinese 
medicine (TCM) named LC978 was found to be competent in reactivating y-globin 
gene in chronic myelogenous leukemia (CML) K562 cell line (Xing., 2003). 
Preliminary study showed that it has an optimal biological dose (OBD) of 12.5ng/ml 
and an IC50 of 841.9ng/ml, in which the IC50 is some 67 times of its OBD. When 
compared to hydroxyurea, the values were 25p,g/ml and 63.11|ig/ml respectively (2.5 
times difference)，indicating that LC978 is an HbF inducing drug with broader safety 
margin. It was also shown that LC978 has an ED50 of only 1/2000 of that of 
hydroxyurea, indicating that LC978 is a drug with better effect at lower dosage. 
Concluding these all, LC978 was determined to be effective drug candidate in 
reactivating y-globin gene in thalassemia patients. 
Study on LC978 induced y-globin expression revealed that, in contrast to 
hydroxyurea that triggers erythroid regeneration, it triggers specific signal 
transduction pathway that leads to specific transcriptional regulation of y-globin 
genes. This was supported by the fact that neither cytotoxic effect nor expression of 
differentiation markers such as glyphorin A and CD71 was detected upon LC978 
induced HbF production. 
Clearly, previous study has shown that LC978 is an HbF inducing agent with better 
efficacy, broader safety margin and more specific induction when compared to 
hydroxyurea. The next step in development of this candidate drug is to elucidate its 
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details in mechanisms involved in y-globin gene reactivation, and this is the main 
theme of the following study. 
1.7 Aim of Study 
In this project, the promoter regulation governing LC978-induced y-globin gene 
regulation will be studied, in which focus will be put onto identifying the 
LC978-responsive element on human y-globin gene promoter. Objectives of this 
study are: 
1. Molecular cloning of the human y-globin gene promoter; 
2. Construction of full and truncated promoter-reporter plasmid constructs; 
3. Assessment of responses of these truncated promoters upon LC978 induction. 
It is believed that the cw-acting DNA elements on promoter that is responsive to 
LC978 induction will be identified following this study, which in turn may lead to 
better understanding of the drug mechanism. 
11 
Chapter 2 Specific Induction of Gamma Globin Gene Transcription in 
K562 Leukemia Cell Line by Lead Compound LC978 
2.1 K562 Cell Line as a Model for Gamma Globin Gene Induction Studies 
K562 cell line is an erythroid progenitor cell line carrying Philadelphia (Phi) 
chromosome that was originally derived from a chronic melogenous leukemia (CML) 
patient in terminal blast crises first established by Lozzio (Lozzio & Lozzio, 1975). 
K562 cells are multipotential hematopoietic malignant cells that are capable of 
spontaneously differentiating into recognizable progenitors of the erythrocytic, 
granulocytic and monocytic sub-lines under the effect of appropriate inducers 
(Koeffler & Golde, 1980). The cell line can differentiate into erythrocytic lineage 
featured by an increase in fetal and embryonic hemoglobin expression level in the 
presence of chemicals such as butyrate (Andersson et al., 1979), hemin (Rutherford 
et al., 1979), hydroxyurea (Erard et al, 1981) and 5-azacytidine (del Senno et al., 
1984). In virtue of the characteristics, K562 cell line has been extensively adopted as 
a model for studies of erythroid differentiation (Rowley et al., 1981) and globin 
genes regulations (Gianni et al., 1982), as well as for development of drug screening 
reporter system for possible fetal hemoglobin inducers (Vadolas et al., 2002). 
In this project, K562 cell line was adopted for in vitro bioassays as well as 
transfection host for study of gamma globin gene promoter regulation. 
2.2 LC978-Induced Fetal Hemoglobin Expression in K562 Cell Line 
In previous study, it has been found that lead compound LC978 can induce K562 
cells to produce elevated level of fetal hemoglobin (Xing, 2003). Xing's study has 
determined the optimal biological dose (OBD) of LC978 with regard to total 
hemoglobin production by in vitro bioassay. Subsequent fluorescence activated cell 
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sorting (FACS) and semi-quantitative reverse transcription polymerase chain reaction 
(RT-PCR) have also been performed to investigate the change in fetal hemoglobin 
level and gamma globin mRNA level. 
In this study, the aim was to investigate the OBD of LC978 with regard to fetal 
hemoglobin production, as well as quantitatively determine the change in gamma 
globin mRNA level upon LC978 treatment at its OBD. The study was divided into 
three parts. The first part was aimed at determining the time and dose response of 
K562 cells on total hemoglobin production under treatment by LC978. It was 
performed by in vitro bioassay resembling that described in previous study (Xing, 
2003). The second part was focused on quantitatively determining the OBD of 
LC978 with regard to fetal hemoglobin production by means of fetal hemoglobin 
quantification enzyme-linked immunosorbent assay (ELISA), utilizing the 
time-response result determined from first part of this study. Final part of the 




2.3.1 Chemicals, Kits and Reagents 
Item Name and Description Manufacturer / Cat. No. 
3,3',5,5'-Tetramethylbenzidine (TMB) Sigma T2885 
31.5-33% Hydrochloric acid (HCl) BDH 10307 
Acetic acid, glacial BDH 100015N 
Antibiotic-Antimycotic (PSF，1OOX)，liquid Invitrogen 15240-062 
Bovine Serum Albumin (BSA), Cohn Fraction V Invitrogen 11018-017 
Cesium chloride (CsCl) Invitrogen 15507-023 
Citric acid monohydrate UNIVAR 160 
Dimethyl sulfoxide (DMSO) Fisher D/4121/PB 17 
Dulbecco's Phosphate-Buffered Saline (D-PBS), powder Invitrogen 21600-010 
Ethanol, absolute Merck 1.00983.2511 
Fetal Bovine Serum (FBS), Certified Invitrogen 16000-069 
Guanidine Thiocyanate Sigma G9277 
Hemoglobin A2, ferrous stabilized human Sigma H0266 
Human Hemoglobin F (HbF) ELISA Quantitation Kit Bethyl Labs E80-136 
Sheep anti-Human HbF Ab, affinity purified Bethyl Labs A80-136A 
Sheep anti-Human HbF Ab, peroxidase-conjugated Bethyl Labs A80-136P 
HbF Calibrator Bethyl Labs RC80-135-4 
Hydrogen peroxide (H2O2, 30% v/v solution) BDH 101284N 
LC978 Solution * 
RPMI Medium 1640，powder Contains L-glutamine and 25 Invitrogen 23400-021 
mM HEPES buffer, but no sodium bicarbonate 
Sodium acetate Sigma S8750 
Sodium bicarbonate (NaHCOs) Sigma S5761/S8875 
Sodium carbonate anhydrous (Na2C03) BDH 102404H 
Sodium chloride (NaCl) Sigma S3014 
Sodium hydroxide (NaOH) Sigma S5881 
Sodium phosphate monobasic anhydrous (NaHzPOj) Sigma S0751 
iQTM SYBR® Green Supermix Bio-Rad 170-8880 
Tris base NHzCCCHzOH); USB 75825 
Tween 20 USB 20605 
Triton X-100 Fluka 93426 
Kindly provided by Dr. Fung's graduate student Dr. Eric Xing. 
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2.3.2 Buffers and Solutions 
Item Name Item Description 
3M Sodium Acetate 61.52g sodium acetate was dissolved in 450ml 
(pH5.2, RNase-free) DEPC-treated Milli-Q H2O, pH was adjusted to pH 5.0 
with glacial acetic acid. Final volume was topped up to 
250ml by Milli-Q H2O. Solution was sterilized by 
autoclave at 121°C for 20 mins. 
5.7M Cesium chloride 87.85g CsCl was dissolved in 91.54ml DEPC-treated 
(RNase-free) Milli-Q H2O. Solution was sterilized by autoclave at 
121°Cfor 20 mins. 
Complete RPMI 1640 One package of RPMI Medium 1640 and 2.0g sodium 
Medium bicarbonate was dissolved in 950ml Milli-Q H2O, pH was 
adjusted to pH 7.2 with IM NaOH. Final volume was 
topped up to IL by Milli-Q H2O. Resulting solution was 
filtered through 0.22|im membrane filter under sterile 
condition. Complete RPMI 1640 medium was made by 
supplementing with 10% FCS (v/v) and 1% PSF (v/v). 
ELISA Blocking Solution 1% BSA (w/v) in IX TBS, freshly prepared 
ELISA Cell Lysis Buffer 1 % Triton X-100 in IX TBS, freshly prepared 
ELISA Coating Buffer 50mM carbonate-bicarbonate at pH 9.6. 0.0795g NaiCOs 
and 0.357g NaHCOa were dissolved in 100ml Milli-Q 
H2O. Solution was stored at 4°C until use. 
ELISA Wash Solution 0.05% Tween 20 (v/v) in IX TBS, freshly prepared 
ELISA Sample Diluent 0.25% Tween 20 (v/v) and 1% BSA (w/v) in IX TBS, 
freshly prepared 
ELISA TMB Stock 5mg/ml TMB in DMSO, stored in airtight glass tube in 
Solution dark at room temperature 
ELISA TMB Substrate 2.555g citric acid and 3.095g NaH2P04 were dissolved in 
Buffer 200ml Milli-Q H2O，pH was adjusted to pH 5.5 with 5M 
NaOH. Final volume was topped up to 250ml by Milli-Q 
H2O. Solution was stored at 4°C until use. 
Guanidine Thiocyanate 4.0M Guanidine Thiocyanate and O.IM Tris-Cl (pH 7.5) in 
Homogenization Buffer DEPC-treated Milli-Q H2O. Solution was filtered through 
(RNase-free) Whatman No.l filter, p-mercaptoethanol was freshly 
added to a final concentration of 0.14M before use. 
LC978 Working Solution 10|ig/ml LC978 in sterile RPMI 1640 medium 
Phosphate Buffered One package of Dulbecco's Phosphate-Buffered Saline 
Saline (PBS) (D-PBS) was dissolved in IL Milli-Q H2O. Solution was 
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sterilized by autoclave at 121°C for 20 mins. 
Tris Buffered Saline 50mM Tris and 140mM NaCl at pH 8.0 
(TBS) 
TMB Stock Solution 5mg/ml TMB in glacial acetic acid 
TMB Working Buffer 5.1 Ig citric acid and 6.19g NaH2P04 were dissolved in 
450ml Milli-Q H2O，pH was adjusted to pH 5.0 with 5M 
NaOH. Final volume was topped up to 500ml by Milli-Q 
H2O. Solution was stored at 4°C until use. 
TMB Working Solution Freshly prepared by mixing 19.8ml TMB working buffer, 
200|il TMB stock solution and 400|il 30% H2O2. 
2.3.3 Cell Line 
Item Name and Description Manufacturer / Cat. No. 
K562 ATCC® CCL-243™ 
The human myeloid leukemia cell line K562 was purchased from ATCC®. The 
K562 cells were cultured in complete RPMI 1640 medium. The cultures were 
maintained under a humidified atmosphere with 95% air / 5% CO2 at 37°C, with cell 
density not exceeding 3x10^ cells/ml. 
2.3.4 Equipments 
Item Name and Description Manufacturer / Cat. No. 
96 MicroWellTM plates NunclonTMA, Round Bottom, Nunc 163320 
Polystyrene, Sterile 
96 Well Clear Flat Bottom Polystyrene High Bind Coming® 9018 
Microplate 
Beckman Ultracentrifuge Tube (Polyallomer) Beckman 326819 
2.3.5 Enzymes 
Item Name and Description Manufacturer / Cat. No. 
M-MLV Reverse Transcriptase Invitrogen 28025-021 
RNaseOUT™ Recombinant Ribonuclease Inhibitor Invitrogen 10777-019 
RQ1 RNase-Free DNase Promega M6101 
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2.3.6 Nucleic Acids 
Item Name and Description Manufacturer / Cat. No. 
dNTP Set, lOOmM Solutions Amersham 27-2035-02 
pd(T)i2-i8 Amersham 27-7858-01 
2.3.7 Oligo Primers 
Primer Name Sequence (5，to 3,) Tm* ( � C ) 
MF214 ACC AC A GTC CAT GCC ATC AC 62 
MF215 TCC ACC ACC CTG TTG CTG TA 62 
MF514 CAG ACG CCA TGG GTC ATT TCA C 68 
MF515 GGT GAA TTC TTT GCC GAA ATG GAT 68 
本 
Tm of each primer was calculated by (A+T) x 2 + (C+G) x 4 
2.4 Methods 
2.4.1 In vitro Bioassay for Total Hemoglobin Production 
a) Preparation of Treatment Cell Culture Plates 
LC978 working solution was diluted to 200ng/ml in complete RPMI 1640 medium. 
200|il of the diluted LC978 solution was transferred to first well of a row of 96-well 
round bottom cell culture plate. 1 OOjil complete RPMI 1640 medium was transferred 
to the rest 11 wells of the row. Serial two-fold dilution was made across each row of 
the cell culture plate. Briefly, 100|xl of solution in the first well was transferred to the 
adjacent well and was mixed thoroughly with lOOjil pre-deposited complete RPMI 
1640 medium, then lOOjj-l of the mixture was transferred further across adjacent well 
of a row. The procedure was repeated until a final of 1/2048 dilution was made in the 
last (12th) well of a row. The setting of 12-well two-fold serial dilution was triplicated, 
and independent plate was prepared for each assay time-point. 
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b) Treatment of K562 Cells by LC978 
K562 cell line propagated under passage with cell density maintained under 3 x 
10^ cells/ml was determined for its cell density by trypan blue exclusion counting on 
a hemocytometer under an inverted light microscope. Cell suspension was then 
diluted to 2 X l i / cells/ml in complete RPMI 1640 medium in a sterile beaker. The 
cells in the suspension (i.e. dynamic cell density) were kept evenly distributed with 
the aid of a spinning magnetic stirrer. lOOjai of the diluted cell suspension was 
transferred to each well of each of treatment 96-well culture plate prepared from 
Section 2.4.1(a). All plates prepared were incubated in a humidified incubator at 
37°C with 5% CO2. 
c) Signal Development 
At each time point, one treatment cell culture plate was centrifuged at 300r.c.f. for 10 
minutes. Supernatant in each well was removed with the aid of a 200|j.l pipette tip 
connected to a peristaltic pump, with the flow rate set at approximately 0.5ml/sec. 
Cell pellet in each well was homogenized in lOO i^l TMB working buffer. Then, 200|il 
of freshly prepared TMB working solution was added to each of treatment wells. The 
plate was incubated at 37°C in dark for 10 minutes. Finally, optical density at 600nm 
(OD600) was measured by SpectraMAX 250 microplate spectrophotometer. 
2.4.2 Detection of Fetal Hemoglobin Production by HbF Sandwich ELISA 
a) Treatment of K562 Cells by LC978 
Procedures for LC978 treatment of K562 cell line were identical to those described 
in Section 2.4.1(a) and Section 2.4.1(b). Only one plate was prepared. The plate was 
incubated for 7 days in a humidified incubator at 37°C with 5% CO2. 
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b) Preparation of Capture Antibody-Coated and BSA-Blocked ELISA Plate 
One day prior to ELISA, sheep anti-human HbF capture antibody was diluted to 
10|ig/ml in coating buffer. lOOjxl of the diluted capture antibody was transferred to 
each well of a 96-well flat bottom high bind microplate. The plate was wrapped with 
laboratory parafilm and was incubated at 4°C overnight. Just prior to ELISA, each 
well of the plate was aspirated, and was washed thrice with 200|il wash solution. 
Then, each well was added with freshly prepared blocking solution. The plate was 
wrapped with laboratory parafilm and was incubated at 37°C for one hour. After 
incubation, each well of the plate was again aspirated, and was washed thrice with 
200p.l wash solution. The plate then ready for antigen (i.e. fetal hemoglobin) capture. 
c) Preparation of K562 Cell Lysates 
At Day 7, the treatment cell culture plate was centrifliged at 300r.c.f. for 10 minutes. 
Supernatant in each well was removed with the aid of a 200|j,l pipette tip connected 
to a peristaltic pump, with the flow rate set at approximately 0.5ml/sec. Cell pellet in 
each well was lysed with 20|il ELISA cell lysis buffer. The plate was incubated at 
4°C for 30 minutes with gentle agitation every 10 minutes. Cell lysate in each well 
was transferred to a 1.8-ml centrifuge tube. The lysates were centrifliged at 
16,100r.c.f. for one minute. Supematants were then diluted at 1:100 (v/v) in sample 
diluent. 
d) Antigen Capture and Signal Development 
100|il of each diluted cell lysates prepared from Section 2.2.2(b)(iii) was added to 
each well of the capture antibody-coated, BSA-blocked ELISA plate prepared from 
Section 2.4.2(b). The plate was wrapped with laboratory parafilm, and was incubated 
at 37°C for 90 minutes. Each well of the plate was then aspirated, and was washed 
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five times with 200|xl wash solution. HRP-conjugated sheep anti-human HbF 
antibody was diluted at 1:5,000 (v/v) in sample diluent. 100)j.1 of the diluted 
conjugate was transferred into each well of the assay plate. The plate was wrapped 
with laboratory parafilm, and was incubated at 37°C for 60 minutes. Again, each well 
of the plate was then aspirated, and was washed five times with 200|il wash solution. 
TMB substrate solution was freshly prepared by mixing 2\i\ 30% H2O2, 200|xl ELISA 
TMB stock solution and 12ml pre-warmed TMB substrate buffer in a polypropylene 
tube. 100|il of the TMB substrate solution was transferred to each well of the assay 
plate. The plate was incubated at 37°C in dark for 10 minutes. Finally, optical density 
at 650nm (OD650) was measured by SpectraMAX 250 microplate 
spectrophotometer. 
2.4.3 Detection of Gamma Globin mRNA Level by Real-time RT-PCR 
a) Treatment of K562 Cells by LC978 
Based on optimal biological dose (OBD) of LC978 determined from Section 2.4.1 
and 2.4.2, K562 cells at initial density of 1 x cells/ml was co-incubated with 
3.125ng/ml LC978 at a final volume of 100ml in complete RPMI 1640 medium. The 
cell culture was incubated for four days in a humidified incubator at 37°C with 5% 
CO2. 
b) Preparation of K562 Cell Lysate in Guanidine Thiocyanate (GT) Solution 
Prior to total RNA isolation, K562 cells were lysed in GT solution. Briefly, 1 x 10^ 
cells were pellet by centrifugation at 300r.c.f. for 10 minutes in a 50-ml 
polypropylene tube. Supernatant was discarded. The cells were then washed twice 
with 50-ml pre-cooled PBS and supernatant was discarded after wash, 
p-mercaptoethanol was freshly added to GT solution at 1:100 (v/v). 3ml of the GT 
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solution was then added dropwise to the cell pellet with continuous agitation. The 
cell lysate in GT solution was stored at -70°C until use. 
c) Isolation of Total RNA from LC978-treated K562 Cells 
Total RNA of LC978-treated K562 cells were isolated based on cesium chloride 
(CsCl) ultracentrifugation method. Prior to RNA work, glassware and metal ware 
were baked at 220°C overnight. Plastic ware (e.g. ultracentrifuge tubes) were treated 
with 0.1% (v/v) DEPC in Milli-Q H2O overnight, and were autoclaved at 121°C for 
20 minutes followed by drying at 65°C. Set of pipettes designated for RNA work and 
RNase-free pipette tips with filter were used for liquid handling throughout the 
experiment. 
To proceed with total RNA isolation, cell lysate prepared from Section 2.4.3(b) were 
thawed in 65°C water bath for 10 minutes with continuous agitation. Thawed cell 
lysate was quickly chilled on ice and was homogenized by passing through a 22-G 
syringe needle for 20 times to shear the nuclear DNA. 2.6ml CsCl solution was 
added to RNase-free ultracentrifuge tube. Cell homogenate in GT solution was gently 
added to the CsCl cushion, and a mark was made at the tube wall to indicate the 
CsCl-GT lysate interphase. The tubes were balanced by addition of GT solution, and 
were centrifliged at 33.7k rpm in Beckman SW55Ti rotor for 18 hours at 18°C. After 
ultracentrifugation, the GT supernatant was aspirated by Pasteur pipette connected to 
a vacuum pump. Bottom CsCl layer was removed by quickly inverting the tube and 
the tube was allowed to drain for a while. Residual liquid droplets on tube wall were 
aspirated by vacuum pump-driven Pasteur pipette. Then, the round bottom fraction of 
the ultracentrifugation tube was cut out using a fresh surgical blade. The clear RNA 
pellet at the bottom was rinsed out by 400|il RNase-free Milli-Q H2O and was 
transferred to a 1.8-ml centrifuge tube. 1ml absolute and 20|il 3M sodium acetate 
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was added to the tube, and was mixed well by vortex. The mixture was incubated at 
ice bath for 30 minutes, and was centrifuged at 16k r.c.f. for 30 minutes. Supernatant 
was removed and the RNA pellet was washed once with 1ml 70% ethanol by 
centrifuged at 16k r.c.f. for five minutes. Supernatant was discarded and the RNA 
pellet was air-dried. The resulting RNA pellet was re-dissolved in 500|il RNase-free 
Milli-Q H2O. The RNA solution was quantified by spectrophotometric analysis and 
was stored at -70°C until use. 
d) cDNA Synthesis from mRNA by Reverse Transcriptase (RT) 
Total RNA purified from Section 2.4.3(c) was treated with RNase-free DNase to 
remove any possible residual DNA that might interfere quantitative PGR result. 
Briefly, l|ig total RNA was treated with lU RNase-free DNase at a final volume of 
lOjjl containing IX Promega RQl RNase-free DNase Reaction Buffer. The reaction 
was performed at 37°C for 30 minutes in an MJ Research PTC-200 thermocycler. At 
the end of incubation, Ijil RQl DNase Stop Solution was added to terminate the 
reaction. The reaction mix was then incubated at 65°C to inactivate DNase. Resulting 
RNA solution was used for reverse transcription. 
Reverse transcription was performed using Moloney Murine Leukemia Virus 
(M-MLV) reverse transcriptase (RT). l|il oligo poly-dTn-ig at 0.1|ig/|il and l|il 
lOmM dNTPs was added to IX RNase-free DNase reaction product. The 
components were mixed well by vortex, and the mixture was incubated at 65°C for 
five minutes in a thermocycler. The tube was then quickly chilled on ice. 4|j,l 5X 
First-Strand Buffer, 2\i\ O.IM DTT and \[l\ RNase 0171™ was added to the tube. 
The mixture was mixed by vortex and spun down, and was incubated at 37°C for two 
minutes. l|il (i.e. 200U) M-MLV RT was added to the tube followed by vortex briefly. 
The reaction mix was incubated at thermocycler with a profile of 37°C for 60 
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minutes followed by 70°C for 15 minutes. Final RT reaction product was then diluted 
with 80)11 DNase-free Milli-Q H2O (i.e. 1:4, v/v) for quantitative PGR. 
e) Real-Time Quantitative Polymerase Chain Reaction (PCR) 
Real-time PCR was performed using BioRad iQ™ SYBR® Green Supermix. Briefly, 
diluted RT reaction product prepared from Section 2.4.3(d) were boiled for 15 
minutes and was quickly chilled on ice. 5|il of boiled sample was mixed with 25|il 
2X iQTM SYBR® Green Supermix and l|il of each of primer pair (i.e. MF214/MF215 
for GAPDH; MF514/MF515 for gamma globin) in a PCR optical tube with final 
volume topped up to 50|xl by DNase-free Milli-Q H2O. The reaction was performed 
in BioRad iCycler thermocycler with a profile listed below: 
Temperature Duration 
95°C 4 mins 
95°C 30 sees n 
Acquisition* 60°C 30 sees 卜40 cycles 
72�C 30 sees � 
• 
Data acquisition was performed at this stage. 
Fluorescent signal was detected and recorded by iQ5 Real-Time PCR Detection 
System and normalized fold expression of gamma globin gene was calculated by iQ5 
Optical System Software. Normalized data were analyzed by one-way analysis of 
variance (ANOVA) in GraphPad Prism® software followed by Tukey's multiple 
comparison test to compare replicate means, where P < 0.05 was considered 
statistically significant. Graph was plotted with all values expressed in Mean 土 
Standard Error of the Mean (SEM). 
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2.5 Results 
a) In vitro Bioassay for Total Hemoglobin Production 
Based on TMB staining method, the total hemoglobin produced by K562 cells 
co-incubated with various concentrations of LC978 was measured. Presence of 
hemoglobin yielded blue precipitates in TMB assay, which the signal intensity was 
detected by spectrophotometer at 600nni wavelength. Over an 8-day experimental 
period, it was found that the hemoglobin produced by K562 cells began to increase 
significantly from Day-3, which then reached their plateaus after Day-5 (Figure 2.2). 
Over different time points throughout the 8-Day experimental period, the total 
hemoglobin production in K562 cells induced by 3.125ng/ml LC978 was determined 
to be the highest (Figure 2.1 and Figure 2.3). 
b) Fetal Hemoglobin Sandwich ELISA 
Fetal hemoglobin produced by K562 cells co-incubated with various concentrations 
of LC978 over a 7-day period was quantified by fetal hemoglobin ELISA. K562 cells 
at 1 X 104 cells/ml co-incubated with different concentrations of LC978 were 
harvested, and cell lysates were prepared by detergent-based method. Total lysates 
were incubated with ELISA plate pre-coated with lO^ig/ml sheep anti-human HbF 
capture antibody, and was probed with 1:5,000 (v/v) HRP-conjugated sheep 
anti-human HbF antibody. Signal was developed by TMB method, and the resulting 
blue colour intensity was measured by spectrophotometer at 650nm wavelength. By 
plotting a sigmoidal dose-response curve (variable-slope) with GraphPad Prism 
software, it was found that the maximum HbF production occurred at LC978 
concentration at 3.125ng/ml (Figure 2.4), where the decrease in HbF production 
higher than this concentration was a result of restricted cell growth due to cell growth 
arrest provoked by the compound (data not shown). 
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c) LC978-Induced Gamma Globin mRNA Accumulation 
Optimal biological dose (OBD) of LC978 was determined to be 3.125ng/ml from 
Section 2.4.2. At this concentration, K562 cells produced the maximum level of fetal 
hemoglobin. K562 cells at 1 x cells/ml initial density were treated with LC978 at 
3.125ng/ml for four days, and RNA was collected for quantification. First-strand 
cDNA was synthesized from CsCl-ultracentrifugation isolated RNA, and then mRNA 
levels of GAPDH and gamma globin were quantified by quantitative real-time PCR, 
where data were analyzed by iQ5 Optical System Software and GraphPad Prism® 
software. Expression level of gamma globin was normalized by that of GAPDH of 
the corresponding individual sample. It was found that the relative expression level 
of gamma globin by K562 cells at Day 4 upon 3.125ng/nil LC978 induction was 
significantly increased when compared to negative controls (i.e. without LC978) at 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































GAPDH-Normalized Expression Level of Gamma Globin Gene 
1.2-1 
E _ 
i 0 . ^ ^ 
I: i 工 讓 
: : : _ • _ 
Day 0 -ve Ctrl Day 4 -ve Ctrl Day 4 LC978 
Condition 
Param*t«r Valiw Data S«t-B Data Set-C Data S«t-0 
TaUa—z»d 
GAPDH-Nofni«li28d Expresftion U v d of Gamma Gtobin G«ne Treated by 10978 
^^••sMy analy of varianc* 
P vakM 0.0005 
P vakM tummary … 
Ar« mtan® signif. drf fvrwit? (P < 0.05丨 Y « 
Number of groupe 3 
F 34.65 
R squared 0.9203 
ANOVA Tabla SS df MS 
Trtatm«nt ( b ^ t v ^ n co l i inns) 0.9706 2 0.4853 
Rasidual (vUthin columns) 0.08404 6 0,01401 
Total 1 055 8 
Tuksy •» Miit ipls Comparison Test Mean Diff q P value 95% CI of d f f 
Day 0 -ve Ctrl v s Day 4 -ve Ctrl 0 2342 3.427 P > 0.05 -0.06229 to 0.5307 
Day 0 - v * Ctrl v s Day 4 LC978 -0.5494 6.040 P < 0.01 -0.8459 to -0.2529 
Day 4 -ve Ctrt v s Day 4 LC978 -0.7836 11.47 P < 0.001 -1.080 to -0.4871 
Figure 2.5 GAPDH-Normalized Expression Level of Gamma Globin Gene. 
K562 cells at an initial density of 1 x cells/ml was co-incubated 
with 3.125ng/ml LC978 in complete RPMI 1640 medium for four days. 
Total RNA was isolated and cDNA was synthesized from mRNA. 
Expression level of GAPDH and gamma globin was quantified by 
real-time PCR. Gamma globin expression level was normalized to 
GAPDH. Cells treated with LC978 for 4 days (Day 4 LC978) showed 
increased gamma globin gene expression level compared to un-treated 
control at Day 0 (Day 0 -ve Ctrl; P < 0.01) and Day 4 (Day 4 -ve Ctrl; 
P < 0.001), where no significant difference was observed between the 
two control groups {P > 0.05). 
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2.6 Discussion 
Main theme of this study was to investigate the OBD of LC978 on K562 cells with 
regard to fetal hemoglobin induction. As described in Section 2.2, LC978 OBD was 
determined by fetal hemoglobin (HbF) quantitation ELISA, and subsequent elevated 
gamma globin mRNA level under LC978 treatment was quantified by real-time 
RT-PCR. 
In previous study (Xing, 2003), OBD of LC978 on K562 cells has already been 
determined by in vitro bioassay of total hemoglobin production. It has been shown 
by FACS analysis that the defined dose of LC978 (i.e. 12.5ng/ml) can induce K562 
cells to produce an increased level of fetal hemoglobin level, and has been shown to 
induce an increased level of gamma globin mRNA by semi-quantitative RT-PCR. 
However, there are still two vital reasons to support for an investigation of the 
LC978 OBD once again. First reason is the concern of batch-to-batch variations of 
the purified lead compound. As a newly discovered lead compound, the extraction 
and purification procedures of LC978 refined throughout its development process. 
Active LC978 provided for use in this project may be at certain extent qualitatively 
or quantitatively different from those purified in early days that has been used in 
previous study, so the OBD may not be the same as that already-defined and a 
determination of OBD for the batch of LC978 used in this project is important. The 
second reason is that there is a need of proof to show a correlation between LC978 
treatment and gamma globin promoter activity. A quantitative analysis of the change 
in gamma globin mRNA accumulation level under LC978 influence can directly 
demonstrate the capability of the compound in inducing gamma globin gene 
transcriptional activity, and thus believably promoter activity. As a result, a 
demonstration of an increased level of gamma globin mRNA accumulation in K562 
cells upon LC978 treatment is critical to the subsequent experimental phases, and 
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found the basis of this entire project. 
From Section 2.4.1, time and dose response in term of total hemoglobin production 
of LC978-treated K562 cells was quantitatively determined by in vitro bioassays 
followed by TMB staining. Over an 8-day experimental period, it was found that the 
total hemoglobin produced by LC978-treated K562 cells began to increase 
significantly from Day-3, which then reached their plateaus after Day-5 (Figure 2.2). 
OBD of LC978 on K562 cells with regard to total hemoglobin production was 
determined to be 3.125ng/ml. Fetal hemoglobin induction by various concentrations 
of LC978 was determined by HbF quantitation sandwich ELISA using specific 
capture and conjugate antibodies. Incubation time for the assay plate was determined 
to be 7 days from Section 2.4.1, where it was shown that a plateau was reached at 
this time point. Result showed that LC978 at 3.125ng/ml induced the highest level 
of fetal hemoglobin level, which was coincide with that determined regarding total 
hemoglobin production. 
Based on the determined LC978 OBD, K562 cells were treated by 3.125ng/ml 
LC978 throughout a 4-day period. Total RNA was collected and gamma globin 
mRNA was quantified by quantitative real-time RT-PCR using human gamma 
globin gene specific primers (GSPs). Result showed that a two-fold increase of 
GAPDH-normalized gamma globin gene expression level was induced, compared to 
un-treated negative control. 
Through this study, it was clearly determined that the OBD of LC978 on K562 cell 
line in term of fetal hemoglobin induction was 3.125ng/ml. The data also clearly 
evidence a correlation between LC978 induction and gamma globin gene 
transcriptional activity. These together found the important basis of further 
investigation into gamma globin gene transcription regulation upon LC978 
induction. 
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Chapter 3 Construction of Promoter-Reporter Plasmid Constructs 
3.1 The Human Gamma Globin Gene Promoter and 3’ Enhancer 
In eukaryotic system, transcription initiation of a gene requires interactions of 
cw-acting DNA elements with trans-ocXmg protein factors, cw-acting DNA elements 
include promoters (McKnight & Kingsbury, 1982; Bensimhon et aL, 1983) and 
enhancers (Khoury & Gruss, 1983). Similar to other eukaryotic genes, the human 
gamma globin genes are controlled under the regulation of proximal promoter 
(Anagnou et al., 1986) and 3’ enhancers (Bodine & Ley, 1987). As a beta-like globin 
gene, high-level transcription activation of the gamma globin genes is also 
developmentally regulated by the p-globin locus control region (LCR) (Raich et al., 
1990; Constantoulakis et al., 1991). 
The human beta-like globin gene locus harbors two copies of gamma globin gene, 
which are the G and A gamma globin genes respectively. Upon alignment of 
nucleotide sequence ranging from +30bp to -220bp from their transcription initiation 
sites (GenBank: NG00007), it was revealed that there is 100% identity between the 
two 5’ flanking sequences, while the percentage identity of the two 5' flanking 
sequences decreases to 97% at -500bp and 86.6% at -1250bp respectively. Despite 
the slight differences in sequence identity, the two promoters show high homology in 
their regulations (Stamatoyannopoulos and Nienhuis, 1994). Nevertheless, the 
minimal promoters that are responsible for activating transcription of the gamma 
globin genes and conferring developmental specificity were found to reside within 
their -202 promoter region, which both contain transcription factors binding sites 
such as GATA (proximal), OCT-1，GATA (distal), CACCC and CCAAT boxes 
(Anagnou et al., 1986; Ryan et al., 2000). However, in recent study, it has been 
reported that responsive elements on gamma globin gene towards pharmaceutical 
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inducer such as sodium butyrate could exist at over -822 of 5' flanking region from 
the transcription initiation site (Pace et al., 2000). On the other hand, 3，enhancer also 
plays a role in gamma globin gene regulation. A region ranges from +400 to +1150 3' 
to the polyadenylation (polyA) site of human A gamma globin gene has been 
identified to be unique enhancer element of the globin gene promoters (Bodine et al., 
1987). It was shown that the enhancer element could augment G gamma globin 
promoter activity in transient transfection promoter-reporter assay. 
In this project, focus was put on human A gamma globin gene proximal promoter 
(-1220 to +30 of CAP site) and human A gamma globin gene 3’ enhancer (+400 to 
+ 1150 to polyA site). In order to study the promoter regulations under influence by 
LC978, a promoter-reporter system was constructed, and promoter deletions were 
made to identify the LC978-responsive elements. 
3.2 SEAP as a Reporter Gene for Promoter Deletion Study 
In this study, secreted human placental alkaline phosphatase (SEAP) gene was used 
as reporter gene for assay of promoter activity (Berger et al., 1988). The human A 
gamma globin gene promoter was placed at the multiple cloning site (MCS) 5' 
upstream to the SEAP gene in commercial vector pSEAP2-Enhancer, where the 
endogenous SV40 enhancer lies 3’ downstream to the SEAP gene was removed and 
was replaced by the human A gamma globin gene 3' enhancer. The whole strategy 
was to construct a promoter-reporter system that mimic the endogenous A gamma 
globin gene in human genome. Then, truncated forms of the A gamma globin gene 
promoter were made by utilizing restriction sites at -754 {BstZll I) and -205 
(PspOM I). It is believed that SEAP reporter gene can enable simple quantification 
assay with low background for K562 transfection experiments, as the K562 cell line 
itself does not produce alkaline phosphatase (Lozzio & Lozzio, 1975). 
34 
3.3 Materials 
3.3.1 Chemicals, Kits and Reagents 
Item Name and Description Manufacturer / Cat. No. 
Ampicillin, anhydrous, 96.0-100.5% (anhydrous basis) Sigma A9393 
Acetic acid, glacial BDH 100015N 
Agar Technical DIFCO 281230 
BactoTM tryptone BD211705 
Bacto® yeast extract DIFCO 0127-17-9 
BigDye® Terminator v2.0 Cycle Sequencing Kit Applied Biosystems 
4314417 
Calcium chloride dihydrate (CaCl2.2H20) Sigma C3881 
Ethanol, absolute Merck 1.00983.2511 
Glycerol USB 16374 
Magnesium chloride hexahydrate (MgCb.SHiO) Sigma M9272 
Magnesium sulfate heptahydrate (MgSCU.THaO) Sigma M2773 
Potassium acetate Sigma P1147 
Potassium chloride (KCl) Sigma P4504 
Rubidium chloride (RbCl) Sigma R2252 
SeaKem® LE agarose BMA 50004 
Sodium acetate Sigma S8750 
Sodium chloride (NaCl) Sigma S3014 
TRIzol® Reagent Invitrogen 15596-018 
Wizard® Plus SV Minipreps DNA Purification System Promega A1460 
3.3.2 Buffers and Solutions 
Item Name Item Description 
IM Potassium Acetate @ 9.82g KOAc was dissolved in 90ml Milli-Q H2O. pH was 
pH 7.5 adjusted to pH 7.5 with 2M acetic acid. Solution was made 
into 10-ml aliquots and was stored at -20°C. 
2M Mg2+Solution Final concentration at IM MgC^ and IM MgS04. 
Solution was sterilized by filtration through a 0.22|im 
syringe filter and was stored at 4°C. 
3M Sodium Acetate @ 61.52g sodium acetate was dissolved in 450ml Milli-Q 
pH 5.0 H2O, pH was adjusted to pH 5.0 with glacial acetic acid. 
Final volume was topped up to 250ml by Milli-Q H2O. 
Solution was sterilized by autoclave at 121°C for 20 mins. 
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Amploo Stock Solution Ampicillin was dissolved in Milli-Q H2O at lOOmg/ml. 
Solution was sterilized by filtration through a 0.22jxm 
syringe filter, made into 1ml aliquots and was stored at 
4 � C . 
LB Medium 5g NaCl, 5g bacto-tryptone and 2.5g bacto-yeast extract 
were dissolved in 500ml Milli-Q H2O. Solution was 
sterilized by autoclave at 121°C for 20 mins. 
LB-Ampioo Medium Cooled LB medium was added with A m p _ stock solution 
to lOO^ig/ml. 
LB-Ampioo Agar LB-Amp_ medium with 1.5% (w/v) bacto-agar. 
RFl Solution Final concentration at lOOmM RbCl, 50mM MnCl2, 
30mM potassium acetate (from IM stock at pH 7.5)， 
lOmM CaCl2, 15% (w/v) glycerol. pH was adjusted to pH 
5.8 with 0.2M acetic acid. Solution was sterilized by 
filtration through a 0.22|j,m syringe filter. 
RF2 Solution Final concentration at lOmM MOPS, lOmM RbCl, 75mM 
CaCl2, 15% (w/v) glycerol. pH was adjusted to pH 6.8 
with NaOH. Solution was sterilized by filtration through a 
0.22|im syringe filter and was stored at 4°C. 
SOB Medium Final concentration at 2% bactoo-tryptone, 0.5% 
bacto-yeast extract, lOmM NaCl and 2.5mM KCl. 
Solution was sterilized by autoclave at 121°C for 20 mins. 
2M Mg2+ solution was added to adjust final concentration 
to 20mM Mg2+. 
SOB Agar SOB medium with 1.5% (w/v) bacto-agar. 
3.3.3 Bacterial Strain 
« 
Item Name and Description Manufacturer / Cat. No. 
Escherichia coli DH5a NEB C2991H 
Genotype: F proA女 B 十 lacf {MacZ)M15 zzfr.TnlO {TQX^)/jhuA2^ 
{argF-lacZ)U169 (080 AilacZ)M15) glnV44 gyrA96 (Haf) recAl 
endAl thi-1 hsdRIl 
3.3.4 Cell Line 
Item Name and Description Manufacturer / Cat. No. 
K562 ATCC® CCL-205™ 
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The human myeloid leukemia cell line K562 was purchased from ATCC®. The 
K562 cells were cultured in complete RPMI 1640 medium. The cultures were 
maintained under a humidified atmosphere with 95% air / 5% CO2 at YTC. 
3.3.5 Enzymes 
Item Name and Description Manufacturer / Cat. No. 
Thermoprime plus DNA polymerase ABgene AB-0301 
Acc65 I NEB R0599S 
ApdL I NEB R0507S 
BstZXl I NEB R0594S 
EcoK I Promega R6355 
Hind III Promega R6041 
Nhe\ NEB R0133S 
Platinum® Pfic DNA polymerase Invitrogen 11708-013 
i ^ O M I NEB V0215S 
Spe\ NEBR0131S 
T4 DNA ligase Promega Ml 804 
T4 DNA polymerase NEB M0203S 
3.3.6 Nucleic Acids 
Item Name and Description Manufacturer / Cat. No. 
dNTP Set, 1 OOmM Solutions Amersham 27-2035-02 
pBlueScript II SK (-) (GenBank: X52330) Stratagene 212206 
pd(T)i2-i8 Amersham 27-7858-01 
pSEAP2-Enhancer (GenBank: U89939) Clontech 6051-1* 
Kindly provided by Dr. Ge's graduate student Ms. Lin Sze-wah. 
3.3.7 Oligo Primers 
Primer Name Sequence (5, to 3，) Tm* (°C) 
MF520 AAT TAA CCC TCA CTA AAG GG 56 
MF521 TAA TAG GAC TCA CTA TAG GGC GA 66 
MF1179 GG GAATTC CAG AGC TTC TGG CAT TAT AAT CTA 74 
GC 
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MF1181 TTG ATA ACC TCA GAC GTT CCA GAA GCG AGT G 92 
MF1182 GG GTTAAC TTT AGG AAT TCA AGG TTT AGT CAG 90 
GTG TAG CAA 
MF1183 CC GTC GAC AAG CTT ATT TTT TTC TCC TTC TTC 88 
ATC TGC CTT 
MF1184 AAA CGA AAC AAA AC A AAC TAG C A 60 
MF1185 TCG GCT GCC TCG CGG TTC 62 
MF1186 GAC AAA CCA CAA CTA GAA TGC A 62 
MF1187 GCT GAC TGG GTT GAA GGC TC 64 
MF1188 TCA GCC AGC ACA CAC ACT TAT C 66 
MF1189 ATA GGT CCA GGA TTT TTG ACG G 64 
• 
Tm of each primer was calculated by (A+T) x 2 + (C+G) x 4 
3.4 Methods 
3.4.1 Molecular Cloning of A-Gamma Globin Gene Promoter and 3’ Enhancer 
into pBIueScript II SK (-) 
a) Design and Synthesis of Oligo Primers 
Oligonucleotide primers were designed for molecular cloning and DNA sequencing 
of human A gamma globin gene promoter and 3' enhancer fragments using Oligo® 
version 6.59 software. MF520/MF521 were T3 and T7 sequencing primer of 
pBlueScript II SK (-) respectively. MF1179/MF1181 were cloning primers for human 
A-gamma globin gene promoter and MF1182/MF1183 were cloning primers for 
human A-gamma globin gene 3' enhancer. Restriction sites were added to these 
primers to facilitate cloning procedures, which were indicated by underline in 
Section 3.3.7. Additional bases were also added to 5' end of these oligo primers to 
increase cleavage efficiencies at the end of DNA fragments, which were indicated by 
bold-type in Section 3.3.7. MF1184/MF1185 were forward and reverse sequencing 
primer flanking multiple cloning site (MCS), and MF1186/MF1187 were forward 
and reverse sequencing primer flanking SV40 enhancer region of pSEAP2-Enhancer 38 
respectively. MF1188/MF1189 were forward and reverse sequencing primers at 
middle region of MF1179/MF1181 -amplified human A-gamma globin gene promoter. 
Primers were designed to minimize stable hairpin or duplex formation and to avoid 
mis-priming. All oligo primers were synthesized by Bio Basic Inc. 
b) Isolation of Genomic DNA from K562 Cells 
Genomic DNA of K562 cells were isolated using TRIzol® reagent with procedures 
according to manufacturer's recommendations. Briefly, cell suspension containing 1 
X 10^ K562 cells was centrifuged at 300r.c.f. for 10 minutes in a 50-ml polypropylene 
tube. The medium was aspirated and the cell pellet was lysed in 1ml TRIzol® reagent. 
The cell homogenate was transferred to a DNase-free 1.8-ml centrifuge tube, and 
was centrifuged at 12k r.c.f. for 10 minutes at 4°C. Resulting supernatant was 
transferred to a fresh 1.8-ml centrifuge tube, and was allowed to stand at room 
temperature for five minutes. Then, 200|il chloroform was added to the cell 
homogenate and the tube was vigorously shaken for 15 seconds. The tube was 
further incubated at room temperature for three minutes. After incubation, the 
mixture was centrifuged at 12k r.c.f. for 15 minutes at 4°C. By then, the mixture was 
separated into upper aqueous phase, middle interphase and lower phase at the bottom. 
The aqueous phase overlying the middle interphase was carefully removed, and 
300)il 100% ethanol was added to the tube containing the interphase and lower phase. 
The components were mixed well by gently inverting the tube several times, and 
then the mixed sample was incubated at room temperature for three minutes. 
Following incubation, DNA content in the tube was pelleted by centrifugation at 
2000r.c.f. for five minutes at 4°C, and the supernatant was discarded. DNA pellet 
was washed twice by 30-minutes incubation of the pellet in 1ml O.IM sodium citrate 
in 10% ethanol, with the solution removed by centrifugation at 2000r.c.f. for five 
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minutes at 4°C after each wash. After two washes, the DNA pellet was resuspended 
in 75% ethanol and was allowed to stand at room temperature for 15 minutes. DNA 
content was pelleted by centrifugation at 2000r.c.f. for five minutes at 4°C, and 
supernatant was discarded. The resulting DNA pellet was air-dried in 37°C incubator, 
and was then dissolved in nuclease-free Milli-Q H2O. The DNA solution was 
quantified by spectrophotometric analysis, and was stored at -20°C until use. 
c) PCR Amplification of Gamma Globin Gene Promoter and 3，Enhancer 
PCR amplification of A-gamma globin gene promoter and 3，enhancer was 
performed using K562 genomic DNA as template. Prior to PCR amplification, the 
isolated K562 genomic DNA was fragmentized by digesting with ApaL I restriction 
endonuclease. Briefly, 5|ig K562 genomic DNA was digested at 37°C for 18 hours 
with 25 units oiApaL I in IX NEB Buffer 4 and IX BSA at a final volume of 100|iL 
The digested DNA was extracted by phenol-chloroform-isoamylalcohol (PCI) 
extraction followed by purification using ethanol precipitation. Briefly, 1:1 (v/v) PCI 
mixture was added to the digestion reaction mix and was mixed by vortex. The 
mixture was centrifliged at 16k r.c.f. for one minute. Clear supernatant was 
transferred to a DNase-free 1.8-ml centrifuge tube. The volume of the supemanant 
was estimated by means of an autopipette. Then, 1/10 volume of 3M sodium acetate 
solution and 2.5 volume of 95% ethanol were added to the supernatant, and were 
mixed by vortex. The mixture was incubated in ice bath for 30 minutes, and then 
centrifuged at 16k r.c.f. for 30 minutes to pellet the DNA. Supernatant was discarded. 
The DNA pellet was washed once with 1ml 70% ethanol. After centrifugation at 16k 
r.c.f. for five minutes, supernatant was discarded and the DNA pellet was air-dried. 
Resulting DNA pellet was re-dissolved in nuclease-free Milli-Q H2O at 0.1|ig/|il. 
High fidelity Platinum® Pjx DNA polymerase was used for amplification of target 
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fragments in order to lower the chance of point mutations that might occur during 
PCR cycles. To amplify the target fragments, 200ng ApaL I-fragmentized K562 
genomic DNA was used as template for each PCR reaction. Corresponding primer 
pairs for A-gamma globin promoter (i.e. MF1179/MF1181) and 3’ enhancer (i.e. 
MF1182/MF1183) were added to the reaction at a final concentration of 0.5pmol/|il 
in 25|il final volume containing IX Platinum® Pfic amplification buffer, ImM MgSCU, 
0.3mM dNTPs and lU Pfx DNA polymerase in a DNase-free thin-wall PCR tube. 
The PCR was performed in an MJ Research PTC-200 thermocycler, with a profile as 
described below: 
Temperature Duration 
94°C 4 mins 
94�C 15 sees n 
56°C 30 sees MO cycles 
68°C 1.5 mins � 
68°C 5 mins 
15°C forever 
5|j.l of each of the PCR products was resolved in 1% agarose gel. Repeats of PCR 
were performed to accumulate adequate amount of target fragments for molecular 
cloning. PCR products for the same target were pooled into one and were stored at 
-20�C until use. 
d) Ligation of PCR Fragments into EcoR V-cut pBlueScript II SK (-) 
pBlueScript II SK (-) was digested with EcoR V to produce two blunt-ends. Briefly, 
1 |ig pBlueScript II SK (-) was digested by 5U EcoR V in a reaction mix with a final 
volume of 20jil containing IX Promega Buffer D and 0.1|j.g/|il acetylated BSA. 
Reaction was performed at 37°C for 1 Shours. The digested DNA was purified by PCI 
extraction and ethanol precipitation. Resulting DNA pellet was re-dissolved in 
nuclease-free Milli-Q H2O at 0.1|ig/}xl. 
41 
Either 1.5|ig EcoR V-digested pBlueScript II SK (-) or 12.5)11 each of PGR products 
produced from Section 3.4.1(c) was loaded into each well of an 1% agarose gel 
containing 0.5|ig/ml ethidium bromide (EtBr), and were resolved at constant 90V 
D.C. for 60 minutes. The gel was then illuminated with longwave UV, and the 
corresponding EtBr-stained bands containing the blunt-end cut vector and target 
fragments were sliced out using a sterile razor blade. The gel slices were loaded into 
a DNase-free self-made centrifugal-filtration apparatus as illustrated below: 
1.8ml centriftige tube ‘ ‘ 0.6ml centrifuge tube 
j f ~ ‘ Whatman No. 1 filter paper 
red-hot wire \ / 
Figure 3.1 Schematic Diagram of Self-made Centrifugal-filtration Apparatus. 
The diagram is a schematic presentation of the centrifugal-filtration unit 
made in our laboratory. Briefly, the 0.6ml centrifuge tube with the 
snap-cap removed was pierced at the bottom with a red-hot platinum 
wire, and then a round piece of Whatman No.l filter was folded into 
conical shape and put into the tube. The 0.6ml centrifuge tube was 
placed inside a 1.8ml centrifuged tube with the snap-cap removed. The 
whole setup was wrapped with aluminum foil and was autoclaved at 
121°Cfor 20 minutes. 
DNA suspension in the gels was extracted by centrifugation at 16k r.c.f. for one 
minute. The suspension was then transferred to a fresh centrifuge tube, and the DNA 
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content was purified by ethanol precipitation. The DNA pellet containing both 
digested vector and PCR fragment was re-dissolved in ligation reaction mix 
containing IX Promega T4 DNA ligase buffer and 3-6 Weiss units of T4 DNA ligase 
at a final volume of 20}al. The ligation reaction was performed at 15°C water bath 
overnight. Resulting reaction product was used directly for bacterial tranformation. 
e) Preparation of E. coli DH5a Competent Cells 
E. coli DH5a was streaked onto SOB agar plate from frozen stock. The plate was 
incubated at 37°C for 18 hours. A single colony was then inoculated into 10ml SOB 
medium to prepare a starter culture, and the culture was incubated at 37°C water bath 
for 16 hours with continuous shaking at 200 rpm. 750)il of DH5a overnight starter 
culture was inoculated into 75ml pre-warmed SOB medium (i.e. 1:100 v/v) in a 1-L 
conical flask, and was incubated at 37°C water bath with continuous shaking at 200 
rpm until OD550 of the culture reached 0.45-0.55 (i.e. 4 - 7 x 10? viable cells/ml). 
50ml of the culture was transferred into a 50-ml polypropylene centrifuge tube, and 
was incubated in ice bath for 15 minutes. Bacterial cells were harvested by 
centrifugation at 1000 r.c.f. at 4°C for 15 minutes with supernatant discarded. The 
cell pellet was then resuspended in 16ml RFl solution (i.e. 1/3 volume of culture). 
The cell suspension was chilled in ice bath for 15 minutes, and was centrifuged at 
1000 r.c.f. at 4°C for 15 minutes where supernatant was discarded. The cell pellet 
was resuspended in 3ml RF2 solution and the cell suspension was incubated in ice 
bath for 15 minutes. Upon the end of incubation, the cell suspension was made into 
110-|al aliquots in strerile 1.8-ml screw-cap vials, and each vial was flash-frozen in 
liquid nitrogen after aliquot. The frozen competent cells aliquots were stored at 
-70°C until use. 
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f) Heat-Shock Transformation of E. coli DH5a Competent Cells 
lOfa.1 of each ligation mix prepared from Section 3.4.1(d) was added to each of llOjil 
freshly thawed aliquots of competent E. coli DH5a under aseptic condition. The 
cells-ligation products suspension was mixed by briefly flicking the tube, then the 
mixture was incubated in ice bath for 30 minutes. Heat-shock transformation was 
performed by quickly transferring the tube to a 42°C water bath, with incubation 
duration of exactly 90 seconds. The tube was then quickly chilled on ice for two 
minutes. 880ia,l LB medium was added to the cells-ligation products mixture, and the 
tube was shaked at 37°C water bath for one hour. Bacterial cells were pelleted by 
centrifugation at 16k r.c.f. for 2 minutes, then 750|il of supernatant was discarded. 
The bacterial pellet was resuspended in the remaining 250|il LB medium by gently 
flicking the tube. The cell suspension was equally spread onto two LB-Amp'®^ agar 
plates pre-spread with IPTG and X-gal. The agar plates were incubated at 37°C for 
18 hours to allow Amp^ bacterial cells to colonize. 
g) PGR Screening and Plasmid Purification of Putative pBlu2SKM-YAP and 
PB1U2SKM-YAE 
White bacterial colonies presented on LB-Amp ^ ^^  plates prepared from Section 
3.4.1(f) were aseptically picked with sterile toothpicks and were inoculated onto new 
grid-lined and numbered LB-Amp _ master plates. The master plates were incubated 
at 37°C for 18 hours. Part of each of the Amp^ colonies was scraped with a sterile 
toothpick, and was resuspended in 50|il Milli-Q H2O in 1.8-ml centrifuge tube. The 
tubes containing the bacterial suspensions were locked and were boiled in water bath 
for 15 minutes. Then they were quickly chilled in ice bath for five minutes. The 
cooled bacterial cell lysates were centrifuged at 16k r.c.f. for five minutes, and the 
clear supematants were used as templates for PGR screening. 
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PCR screening was aimed at amplifying the target promoter and enhancer fragments 
using primer pairs MF1179/MF1181 and MF1182/MF1183. Primer pair 
MF520/MF521 flanking the vector MCS were also used for insert orientation checks. 
PCR amplification was performed using ABgene Thermoprime Plus DNA 
polymerase. In each PCR, 5\x\ of each boiled template prepared as previously 
described was added to reaction mix containing IX PCR buffer IV, 1.5mM MgCl!, 
0.2mM dNTPs, 0.5pmol/|il of each primer and 0.5U polymerase at a final volume of 
25|il in a DNase-free thin-wall PCR tube. The PCR was performed in an MJ 
Research PTC-200 thermocycler, with a profile as described below: 
Temperature Duration 
96�C 4 mins 
96�C 30 sees n 
54°C 30 sees |-35 cycles 
72�C 1 min � 
72�C 5 mins 
15°C forever 
5|0,1 of each PCR product was resolved in 1% agarose gel with 0.5|ig/ml EtBr. The gel 
containing EtBr-stained bands were visualized under UV illumination by BioRad 
GelDoc XR system, and the image was captured and digitalized by BioRad Quantity 
One® software. 
h) Isolation of Putative pBluZSKM-yAP and pBlu2SKM-yAE Plasmid DNA 
Each of bacterial colonies that showed a band with desirable size upon PCR 
screening in Section 3.4.1(g) were inoculated from master plates into 25ml 
L B - A m p i � broth in a 250-ml conical flask. The cultures were incubated at 37°C 
water bath with continuous shaking at 200 r.p.m. for 16-18 hours. 
The plasmid DNA in the bacterial cells were isolated and purified by Promega 
Wizard® Plus SV Minipreps DNA Purification System according to manufacturer's 
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recommendations. To purify the plasmid DNA, 15ml of each overnight bacterial 
culture was transferred into a fresh 50-ml conical bottom polypropylene centrifuge 
tube. The bacterial cells were pelleted by centrifugation at 6000r.c.f. for 10 minutes 
at 4°C and supernatant was carefully discarded. Bacterial cell pellet was then 
resuspended in 250^1 Cell Resuspension Solution by gently pipetting ups and downs, 
and the suspension was transferred into a DNase-free 1.8-ml centrifuge tube. 
Bacterial cells were completely lysed by adding 250|xl Cell Lysis Solution into the 
tube followed by gently inverting the tube several times. 10|j,l Alkaline Protease 
Solution was then added into the cell lysate and was mixed by gentle inversions. The 
well-mixed lysate-protease mixture was incubated at room temperature for five 
minutes, and then 350|il Neutralization Solution was added to the mixture with 
mixing by inversions. The neutralized lysate was centrifuged at 16k r.c.f. for 60 
minutes, where the lysate separated into bottom bulky debris and upper clear 
supernatant layers. 
The clear supernatant of each miniprep reaction was transferred into a fresh 
minicolumn-collection tube assembly, and was centrifuged at 16k r.c.f. for one 
minute. Flowthrough in the collection tube was discarded, and the filter disc in the 
minicolumn was washed twice with 750|j,l and 250|il Column Wash Solution 
respectively. Spun-dried minicolumn was then placed into a DNase-free 1.8-ml 
centrifuge tube, and 100|j.1 65°C-pre-warmed DNase-free Milli-Q H2O was added to 
the filter disc. The minicolumn-centrifuge tube assembly was covered with 
laboratory parafilm, and was incubated at room temperature for five minutes. The 
assembly was then centrifuged at 16k r.c.f. for one minute, and the resulting DNA 
solution collected was quantified by spectrophotometric analysis by means of a 
spectrophotometer. 
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i) Nucleotide Sequencing of Putative pBlulSKM-yAP and pBluISKM-yAE 
Putative pBlu2SKM-YAP and pBlu2SKM-yAE plasmid DNA purified from Section 
3.4.l(i) were sequenced for insert fragments and region flanking the MCS. DNA 
sequencing was performed by cycle sequencing reaction based on BigDye® 
Terminator v3.1 Cycle Sequencing Kit. Briefly, 200ng of each plasmid DNA sample 
purified were added into a cycle sequencing reaction mix containing 4|il 
Terminator-Ready Reaction Mix and 1.6pmol of each primer at a final volume of 
lOjil in a DNase-free thin-wall PCR tube. The cycle sequencing reaction was 
performed in an MJ Research PTC-200 thermocycler using a profile as listed below: 
Temperature Duration 
96°C 30 sees n 
50�C 15 sees 卜25 cycles 
64�C 4 mins � 
4°C forever 
Each of the resulting cycle sequencing products was transferred into a DNase-free 
1.8-ml centrifuge tube, and the DNA content was desalted and purified by ethanol 
precipitation. DNA pellet was air-dried, and was re-dissolved in 10|il Hi-DiTM 
formamide by vigorous vortex. Each of DNA suspensions was then transferred to 
each well of a Micro Amp® Optical 96-Well Reaction Plate. The plate was heated at 
95°C for two minutes in PTC-200 thermocycler and was quickly chilled on ice bath. 
The reaction plate was then placed into ABI PRISM® 3100 Genetic Analyzer for 
capillary electrophoresis of the cycle sequencing products, and the corresponding 
emission peaks were detected and raw data was recorded and analyzed by ABI 
PRISM® 3100 Genetic Analyzer Data Collection software. Raw emission peak data 
was converted to nucleotide sequence by ABI PRISM® 3100 Genetic Analyzer 
Sequencing Analysis software, and was aligned with corresponding authentic 
nucleotide sequence in AlignX program in Vector NTI Suite 9.0.0 software. 
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Overlapping sequencing data acquired using oligo primer bound on different 
locations of the target fragments were analyzed together for complete nucleotide base 
reading of the full-length fragment. Plasmid DNA constructs at this stage were 
annotated pBlu2SKM-YAP (i.e. containing A-gamma globin gene promoter) and 
pBlu2SKM-yAE (i.e. containing A-gamma globin gene 3' enhancer) respectively. 
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j) Graphical Summary of Section 3.4.1 Sub-cloning Procedures 
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Figure 3.2 Molecular Cloning of Human A Gamma Globin Gene Promoter. 
Human A gamma globin gene promoter amplified by MF1179/MF1181 
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Figure 3.3 Molecular Cloning of Human A Gamma Globin Gene 3' Enhancer. 
Human A gamma globin gene 3' enhancer amplified by 
MFll82/MFl 183 primer pair was inserted into EcoR V-cut pBlueScript 
II SK (-) plasmid vector. 
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3.4.2 Molecular Cloning of A-Gamma Globin Gene Promoter and 3' Enhancer 
into pSEAP2-Enhaiicer 
a) Sub-cloning of Promoter Fragment into pSEAP2-Enhancer 
pBlu2SKM-yAP plasmid DNA was first digested by Hind III restriction 
endonuclease. Briefly, 10|ig pBlu2SKM-7AP was digested by 50U Hind III in a 
reaction mix with a final volume of 200|j,l containing IX Promega Buffer E and 
0.1|j.g/}j.l acetylated BSA. The reaction mix was well-mixed by vortex, and was made 
into 40-|il aliquots in 1.8-ml centrifuge tubes. All aliquots were incubated at 37°C for 
18 hours. 6}a.g pSEAP2-Enhancer plasmid DNA was digested with Hind III in similar 
fashion, with appropriate down-scale of reaction volume. 
Both Hind Ill-digested pBlu2SKM-7AP and pSEAP2-Enhancer were extracted by 
PCI extraction and desalted by ethanol precipitation. Resulting DNA pellet was 
re-dissolved in DNase-free Milli-Q H2O at final concentration of 0.1|ig/|a.l. 
Hind Ill-digested pBlu2SKM-yAP and pSEAP2-Enhancer were further cut with Spe I 
or Nhe I respectively. To do so, either lOjig Hind Ill-digested pBlu2SKM-yAP or 6|ig 
Hind Ill-digested pSEAP2-Enhancer was loaded into digestion reaction mix 
containing IX NEB Buffer 2，IX BSA and 0.25U/|xl Spe I or Nhe I respectively with 
corresponding reaction scale at l|ig DNA/20|j.l. Both reaction mixes were mixed well 
by vortex, and were made into 40-|il aliquots in 1.8-ml centrifuge tubes. All reaction 
aliquots were incubated at 37°C for 18 hours. 
Reaction products were then extracted by PCI extraction and desalted by ethanol 
precipitation. Resulting DNA pellet was re-dissolved in DNase-free Milli-Q H2O at 
final concentration of 0.1|j,g/|j,l. 
Purification of target fragments of desirable sizes by agarose gel electrophoresis was 
same as described in Section 3.4.1(d). Extracted DNA fragments of human A-gamma 
globin gene promoter fragment (i.e. 1.3kb band) and linearized pSEAP2-Enhancer 
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were dissolved in ligation reaction mix containing IX Promega T4 DNA ligase 
buffer and 3-6 Weiss units of T4 DNA ligase at a final volume of 20|j,l. The ligation 
reaction was performed at 15°C water bath overnight. Resulting reaction product was 
used directly for tranformation into E. coli DH5a competent cells as described in 
Section 3.4.1(f). 
PCR screening [Section 3.4.1(g)], isolation of plasmid DNA from desirable bacterial 
clones [Section 3.4.1(h)] and cycle sequencing reaction [Section 3.4.1(i)] were 
performed as described in previous sections. Plasmid DNA construct obtained at this 
stage was annotated p 1224yAP-SEAP2-Enhancer. 
b) Sub-cloning of 3，Enhancer Fragment into P1224YAP-SEAP2 
Both pBlu2SKM-yAE and p 1224yAP-SEAP2-Enhancer were digested with Him II. 
Briefly, either lOng pBlu2SKM-YAE or 4|ig p 1224^AP-SEAP2-Enhancer was loaded 
into digestion reaction mix containing IX NEB Buffer 3，IX BSA and 0.25U/|il Hinc 
II with corresponding reaction scale at Ijxg DNA/20|il. Both reaction mixes were 
mixed well by vortex, and were made into 40-|j,l aliquots in 1.8-ml centrifuge tubes. 
All reaction aliquots were incubated at 37°C for 18 hours. 
Reaction products were then extracted by PCI extraction and desalted by ethanol 
precipitation. Resulting DNA pellet was re-dissolved in DNase-free Milli-Q H2O at 
final concentration of 0.1|ig/|il. 
Purification of target fragments of desirable sizes by agarose gel electrophoresis was 
same as described in Section 3.4.1(d). Extracted DNA fragments of human A-gamma 
globin gene 3' enhancer fragment (i.e. 0.7kb band) and linearized 
p 1224YAP-SEAP2-Enhancer without SV40 enhancer (i.e. 6kb band) were dissolved 
in ligation reaction mix containing IX Promega T4 DNA ligase buffer and 3-6 Weiss 
units of T4 DNA ligase at a final volume of 20|j.l. The ligation reaction was 
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performed at 15°C water bath overnight. Resulting reaction product was used 
directly for tranformation into E. coli DH5a competent cells as described in Section 
3.4.1(f). 
PCR screening [Section 3.4.1(g)], isolation of plasmid DNA from desirable bacterial 
clones [Section 3.4.1(h)] and cycle sequencing reaction [Section 3.4.1(1)] were 
performed as described in previous sections. Plasmid DNA construct obtained at this 
stage was annotated p 1 224YAP-SEAP2-YAE. 
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c) Graphical Summary of Section 3.4.2 Sub-cloning Procedures 
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Figure 3.4 Sub-Cloning of Human A Gamma Globin Gene Promoter into 
pSEAP2-Enhancer. pBlulSKM-yAP was cut with Hind III and Spe I 
to release the promoter fragment. pSEAP2-Enhancer was linearized by 
cutting with Hind III and Nhe 1. Nhe I and Spe I restriction 
endonuclases generated compatible sticky ends on each end of 
promoter fragment and pSEAP2-Enhancer vector, while the other sides 
of both were Hind III blunt ends. Finally, directional cloning was 
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Figure 3.5 Sub-Cloning of Human A Gamma Globin Gene 3' Enhancer into 
pl224YAP-SEAP2-Enhancer. pBlu2SKM-yAE and pl224yAP-SEAP2 
-Enhancer were cut with Hinc II to yield the human A-gamma globin 
gene 3，enhancer fragment and release the SV40 enhancer fragment 
respectively. Target fragments resolved in agarose gels were acquired 
and purified. As both ends of fragments and linearized vector were 
blunt ended, non-directional cloning was performed. After 
transformation and PCR screening, desirable clones with correct insert 
size and orientation were identified and selected. 
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3.4.3 Construction of pl2247AP-SEAP2-YAE Promoter Deletions Constructs 
a) Restriction Digestion at 5' End of A-Gamma Promoter Deletions 
Construction of promoter deletion constructs began with restriction endonuclease 
digestion of p 1224yAP-SEAP2-YAE by Acc65 I at 5' end of putative deletions. 
8}ig/|j.l p 12247AP-SEAP2-YAE was mixed with 25U Acc65 I in reaction mix 
containing IX NEB Buffer 3 and IX BSA at a final volume of 160|il. The reaction 
mix was mixed well by vortex and was made into 40-)j,l aliquots in 1.8-ml centrifuge 
tubes. All reaction aliquots were incubated at 37°C for 18 hours. Resulting linearized 
DNA fragments were extracted by PCI extraction and desalted by ethanol 
precipitation as described in Section 3.4.1(c). The DNA pellet was then re-dissolved 
in DNase-free Milli-Q H2O at a final concentration of 0.1|j,g/|al. 
b) Restriction Digestion at 3’ Ends of A-Gamma Promoter Deletions 
Linearized DNA prepared from Section 3.4.3(a) was digested either by BstZXl I or 
PspOM I to generate 470-bp or 1019-bp 5' promoter deletions respectively. 
To generate 470-bp 5' deletion, 3|ig Acc6S I-linearized p 1224yAP-SEAP2-YAE from 
Section 3.4.3(a) was further digested by 7.5U BstZVJ I in reaction mix containing IX 
NEB Buffer 3 and IX BSA at a final volume of 60|il. The reaction mix was mixed 
well by vortex and was made into 30-|j.l aliquots in 1.8-ml centrifuge tubes. All 
reaction aliquots were incubated at 37°C for 18 hours. The reaction mixes were then 
heat-inactivated at 65°C for 20 minutes and were pooled together. Digested sample 
was stored at -20°C. 
To generate 1019-bp 5, deletion, S^ig Acc65 I-linearized p 12247AP-SEAP2-YAE 
from Section 3.4.3(a) was further digested by 45U P^pOM I in reaction mix 
containing IX SE Buffer Y and IX BSA at a final volume of 60|il. The reaction mix 
was mixed well by vortex and was made into 30-|il aliquots in 1.8-ml centrifuge 
56 
tubes. All reaction aliquots were incubated at 37°C for 18 hours. The reaction mixes 
were then heat-inactivated at 65°C for 20 minutes and were pooled together. 
Digested sample was stored at -20°C. 
c) Blunting 5'-overhangs and Self-Ligation of Linearized Plasmid Constructs 
Digestion mixes of Acc65 VBstZXl I and Acc65 VPspOM I double-digested 
p 1224yAP-SEAP2-yAE from Section 3.4.3(b) were incubated at 37°C for 10 minutes. 
Upon the end of incubation, 3U T4 DNA polymerase was added to each of digestion 
mixes, and incubation at 37°C continued for further 10 minutes. Then, 0.62|il lOmM 
dNTPs was added to each of the digestion mixes to make dNTPs final concentration 
at 100|iM. Both digestion mixes were mixed well by vortex and were incubated at 
37°C for 30 minutes. Upon the end of incubation, the digestion mixes were purified 
by agarose gel electrophoresis as described in Section 3.4.1(d). Each of linearized 
p 1 224YAP-SEAP2-7AE fragments either with 470-bp 5' promoter deletion (i.e. 6kb 
band) or 1019-bp 5' promoter deletion (i.e. 5.5kb band) was dissolved in ligation 
reaction mix containing IX Promega T4 DNA ligase buffer and 2.25-4.5 Weiss units 
of T4 DNA ligase at a final volume of 15|a,l. The ligation reaction was performed at 
15°C water bath overnight. Resulting auto-ligation products were used directly for 
tranformation into E. coli DH5a competent cells as described in Section 3.4.1(f). 
PCR screening [Section 3.4.1(g)], isolation of plasmid DNA from desirable bacterial 
clones [Section 3.4.1(h)] and cycle sequencing reaction [Section 3.4.1(i)] were 
performed as described in previous sections. Plasmid DNA constructs obtained at 
this stage were annotated p754yAP-SEAP2-yAE (i.e. with 470-bp 5, deletion) and 
p205yAP-SEAP2-YAE (i.e. with 1019-bp 5，deletion) respectively. 
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d) Graphical Summary of Section 3.4.3 5，Deletions Procedures 
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Figure 3.6 Generation of 5’ Deletions in Human A Gamma Globin Gene 
Promoter in P1224YAP-SEAP2-YAE. Circular plasmid construct 
p 1 224YAP-SEAP2-YAE (A) was cut with Acc65 I to its linearized form 
(B). It was then digested by BstZM I or PspOM I to generate 470-bp or 
1019-bp 5' deletions at the promoter, producing p754yAP-SEAP2-YAE 
(C) and P205YAP-SEAP2-YAE (D). These linearized DNA were blunt 




Specific primers were designed to amplify human A gamma globin gene promoter 
fragment and 3’ enhancer fragment from genomic DNA isolated from K562 cell line. 
The two PCR fragments were sub-cloned into pBlueScript II SK (-) and were 
sequenced. Cycle sequencing results showed that both sequences were 100% 
identical to the authentic sequence on GenBank (GenBank: NG000007) at 
46535bp-47790bp for promoter and 49726bp-50482bp for 3，enhancer. The promoter 
fragment was then sub-cloned into MCS at 5, upstream to SEAP gene of commercial 
vector pSEAP2-Enhancer at an orientation same as that in human genome. The SV40 
3' enhancer in pSEAP2-Enhancer was removed and was replaced by A gamma globin 
gene 3' enhancer. Sequencing results showed 100% identity to authentic sequence as 
well as correct ligation sites (Figure 3.7 and 3.8). This plasmid construct was then 
digested with Acc65 HBstZXl I or Acc65 1/PspOM I restriction endonuclease pairs to 
produce promoter truncations at its 5' ends. 5' overhangs of these unique cutting sites 
were then filled in by T4 DNA polymerase and were ligated. Sequencing results 
showed that truncated forms of A gamma promoter at -754 (Figure 3.9) and -205 
(Figure 3.10) were correctly constructed. 
Resulting promoter-reporter constructs were annotated p 12247AP-SEAP2-yAE, 
p754yAP-SEAP2-YAE and p205YAP-SEAP2-yAE respectively, indicating the 
lengths of promoters from their transcription initiation sites. Figure 3.11, 3.12 and 
3.13 display the plasmid maps of the three constructs. 
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a) Nucleotide Sequence Confirmed by Cycle Sequencing 
M F 1 1 8 4 ACC65I 
'•••^W^^'U.iPJUUU, VWwW 
6 5 1 5 AAACGAAACA AAACAAACTA GCAAAATAGG CTGTCCCCAG TGCAAGTGCA GGTGCCAGAA CATTTCTCTA TCGATAGGTA 
TTTGCTTTGT TTTGTTTGAT CGTTTTATCC GACAGGGGTC ACGTTCACGT CCACGGTCTT GTAAAGAGAT AGCTATCCAT 
Acc661 Human A-gamma globin gene -1224 promo 
5 CCGAGCTCTT ACGCGTpCTA GTGGATCCCC CGGGCTGCAG GAATTCGATG GGAATTCCAG AGCTTCTGGC ATTATAATCT 
GGCTCGAGAA TGCGCACGAT CACCTAGGGG GCCCGACGTC CTTAAGCTAC CCTTAAGGTC TCGAAGACCG TAATATTAGA 
MFI 口 
Human A-^amma globin pene -1224 promoter 
8 5 AGCAAGGTTA GAGATCATGG ATCACTTTCA GAGAAAAACA AAAACAAACT AACCAAAAGC AAAACAGAAC CAAAAAACCA 
TCGTTCCAAT CTCTAGTACC TAGTGAAAGT CTCTTTTTGT TTTTGTTTGA TTGGTTTTCG TTTTGTCTTG GTTTTTTGGT 
Human A-gamma globin gene -1224 promoter 
1 6 5 CCATAAATAC TTCCTACCCT GTTAATGGTC CAATATGTCA GAAACAGCAC TGTGTTAGAA ATAAAGCTGT CTAAAGTACA 
GGTATTTATG AAGGATGGGA CAATTACCAG GTTATACAGT CTTTGTCGTG ACACAATCTT TATTTCGACA GATTTCATGT 
Human A-^ amma globin pene -1224 promoter 
2 4 5 CTAATATTCG AGTTATAATA GTGTGTGGAC TATTAGTCAA TAAAAACAAC CCTTGCCTCT TTAGAGTTGT TTTCCATGTA 
GATTATAAGC TCAATATTAT CACACACCTG ATAATCAGTT ATTTTTGTTG GGAACGGAGA AATCTCAACA AAAGGTACAT 
力？” •卞ai^ tT^ � g!?bin e^ne -1224 promoter 
3 2 5 CACGCACATC TTATGTCTTA GAGTAAGATT CCCTGAGAAG TGAACCTAGC ATTTATACAA GATAATTAAT TCTAATCCAC 
GTGCGTGTAG AATACAGAAT CTCATTCTAA GGflACTCTTC ACTTGGATCG TAAATATGTT CTATTAATTA AGATTfiGGTG 
Human A-gamma^ lobin e^ne -1224 promoter 
4 0 5 AGTACCTGCC AAAGAACATT CTACCATCAT CTTTACTGAG CATAGAAGAG CTACGCCAAA ACCCTGGGTC ATCAGCCAGC 
TCATGGACGG TTTCTTGTAA GATGGTAGTA GAAATGACTC GTATCTTCTC GATGCGGTTT TGGGACCCAG TAGTCGGTCG 
m f ” 8 8 istzTTi 
Human A-^ amma gjobin pene -1224 promoter 
4 8 5 ACACACACTT ATCCAGTGGT AAATACACAT CATCTGGTGT ATACATACAT ACCTGAATAT GGAATCAAAT ATTTTTCTAA 
TGTGTGTGAA TAGGTCACCA TTTATGTGTA GTAGACCACA TATGTATGTA TGGACTTATA CCTTAGTTTA TAA7VAAGATT 
Human A-gamrna globin ^ene -1224 promoter 
5 6 5 GATGAAACAG TCATGATTTA TTTCAAATAG GTACGGATAA GTAGATATTG AGGTAAGCAT TAGGTCTTAT ATTATGTAAC 
CTACTTTGTC AGTACTAAAT AAAGTTTATC CATGCCTATT CATCTATAAC TCCATTCGTA ATCCAGAATA TAATACATTG 
Huma?今y jiene-1224 prornoter 
6 4 5 ACTAATCTAT TACTGCGCTG AAACTGTGGC TTTATAGAAA TTGTTTTCAC TGCACTATTG AGAAATTAAG AGATAATGGC 
TGATTAGATA ATGACGCGAC TTTGACACCG AAATATCTTT AACAAAAGTG ACGTGATAAC TCTTTAATTC TCTATTACCG 
Human A-garnrna globin pene -1224 promoter 
7 2 5 AAAAGTCACA AAGAGTATAT TCAAAAAGAA GTATAGCACT TTTTCCTTAG AAACCACTGC TAACTGAAAG AGACTAAGAT 
TTTTCAGTGT TTCTCATATA AGTTTTTCTT CATATCGTGA AAAAGGAATC TTTGGTGACG ATTGACTTTC TCTGATTCTA 
Human A-gamma gjobin gene -1224 promoter 
8 0 5 TTGTCCCGTC AAAAATCCTG GACCTATGCC TAAAACACAT TTCACAATCC CTGAACTTTT CAAAAATTGG TACATGCTTT 
AACAGGGCAG TTTTTAGGAC CTGGATACGG ATTTTGTGTA AAGTGTTAGG GACTTGAAAA GTTTTTAACC ATGTACGAAA 
MF1189 
Human A-gamma globin gene -1224 promoter 
8 8 5 AGCTTTAAAC TACAGGCCTC ACTGGAGCTA GAGACAAGAA GGTAAAAAAC GGCTGACAAA AGAAGTCCTG GTATCCTCTA 
TCGAAATTTG ATGTCCGGAG TGACCTCGAT CTCTGTTCTT CCATTTTTTG CCGACTGTTT TCTTCAGGAC CATAGGAGAT 
H u m a ? 今 宇 j o b i n ^ene -1224 promoler 
9 6 5 TGATGGGAGA AGGAAACTAG CTAAAGGGAA GAATAAATTA GAGAAAAACT GGAATGACTG AATCGGAACA AGGCAAAGGC 
ACTACCCTCT TCCTTTGATC GATTTCCCTT CTTATTTAAT CTCTTTTTGA CCTTACTGAC TTAGCCTTGT TCCGTTTCCG 
Human A-gamma globin gone -1224 promoter 
PspOMI 
1 0 4 6 TATAAAAAAA ATTAGCAGTA TCCTCTTGGG GGCCCCTTCC CCACACTATC TCAATGC7VAA TATCTGTCTG AAACGGTCCC 
ATATTTTTTT TAATCGTCAT AGGAGAACCC CCGGGGAAGG GGTGTGATAG AGTTACGTTT ATAGACAGAC TTTGCCAGGG 
Human A-gamma globin pane -1224 prornoter 
1 1 2 5 TGGCTAAACT CCACCCATGG GTTGGCCAGC CTTGCCTTGA CCAATAGCCT TGACAAGGCA AACTTGACCA ATAGTCTTAG 
ACCGATTTGA GGTGGGTACC CAACCGGTCG GAACGGAACT GGTTATCGGA ACTGTTCCGT TTGAACTGGT TATCAGAATC 
Human A-^amma globin ^ene -1224 promoter 
1 2 0 5 AGTATCCAGT GAGGCCAGGG GCCGGCGGCT GGCTAGGGAT GAAGAATAAA AGGAAGCACC CTTCAGCAGT TCCACACACT 
TCATAGGTCA CTCCGGTCCC CGGCCGCCGA CCGATCCCTA CTTCTTATTT TCCTTCGTGG GAAGTCGTCA AGGTGTGTGA 
MF116 
~ 一 ‘ SEAP 
1 2 8 5 CGCTTCTGGA ACGTCTGAGG TTATCAAATC AAGCTTCGAA TCGCGAATTC GCCCACCATG CTGCTGCTGC TGCTGCTGCT 
GCGiy^GACCT TGCAGACTCC AATAGTTTAG TTCGAAGCTT AGCGCTTAAG CGGGTGGTAC GACGACGACG ACGACGACGA 
MF1181 
SI£AP 
1 3 6 5 GGGCCTGAGG CTACAGCTCT CCCTGGGCAT CATCCCAGTT GAGGAGGAGA ACCCGGACTT CTGGAACCGC GAGGCAGCCG 
CCCGGACTCC GATGTCGAGA GGGACCCGTA GTAGGGTCAA CTCCTCCTCT TGGGCCTGAA GACCTTGGCG CTCCGTCGGC 
MF1185 
I “ ‘ 
1 4 4 5 A 
T 
^ 
Figure 3.7 Sequence Flanked by MF1184/MF1185 in pl224YAP-SEAP2-yAE. 
Human A-gamma globin gene promoter amplified by MF1179/MF1181 
was inserted into MCS of pSEAP2-Enhancer. 
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MF1186 
2 9 2 3 GACAAACCAC AACTAGAATG CAGTGAAAAA AATGCTTTAT TTGTGAAATT TGTGATGCTA TTGCTTTATT TGTAACCATT 
CTGTTTGGTG TTGATCTTAC GTCACTTTTT TTACGAAATA AACACTTTAA ACACTACGAT AACGAAATAA ACATTGGTAA 
Human 今：严 mmagj?b in j | ^ne enhancer 
MF1182 
3003 ATAAGCTGCA ATAAACAAGT TAACTTTAGG AATTCAAGGT TTAGTCAGGT GTAGCAATTC TATTTTATTA GGAGGAATAC 
TATTCGACGT TATTTGTTCA ATTGAAfiTCC TTAAGTTCCA RATCAGTCCA CATCGTTAAG ATTVAAfiTAAT CCTCCTTATG 
Human A-gamma globin gene enhancer 
3 0 8 3 TATTTCTAAT GGCACTTAGC TTTTCACAGC CCTTGTGGAT GCCTAAGAAA GTGAAATTAA TCCCATGCCC TCAAGTGTGC 
ATAAAGATTA CCGTGAATCG AAAAGTGTCG GGAACACCTA CGGATTCTTT CACTTTAATT AGGGTACGGG AGTTCACACG 
h j u m 〒？今〒巧 globin gene enhancer 
3 1 6 3 AGATTGGTCA CAGCATTTCA AGGGAGAGAC CTCATTGTAA GACTCTGGGG GAGGTGGGGA CTTAGGTGTA AGAAATGAAT 
TCTAACCAGT GTCGTAAAGT TCCCTCTCTG GAGTAACATT CTGAGACCCC CTCCACCCCT GAATCCACAT TCTTTACTTA 
Human 今-pamn^a plpt^in 马?ne，二h 〒！ic 〒！ 
3 2 4 3 CAGCAGAGGC TCACAAGTCA GCATGAGCAT GTTATGTCTG AGAAACAGAC CAGCACTGTG ;\GATCAAAAT GTAGTGGGAA 
GTCGTCTCCG AGTGTTCAGT CGTACTCGTA CAATACAGAC TCTTTGTCTG GTCGTGACAC TCTAGTTTTA CATCACCCTT 
Human A-gamma globin gene enhancer 
3 3 2 3 GAATTTGTAC AACATTAATT GGAAGGCTTA CTTAATGGAA TTTTTGTATA GTTGGATGTT AGTGCATCTC TATAAGTAAG 
CTTAAACATG TTGTAATTAA CCTTCCGAAT GAATTACCTT AAAAACATAT CAACCTACAA TCACGTAGAG ATATTCATTC 
”义m义？今-贫〒 globin ^ene enhancer 
3 4 0 3 AGTTTAATAT GATGGTGTTA CGGACCTAAT GTTTGTGTCT CCTCAAAATT CACATGCTGA ATCCCCAACT CCCAACTGAC 
TCAAATTATA CTACCACAAT GCCTGGATTA CAAACACAGA GGAGTTTTAA GTGTACGACT TAGGGGTTGA GGGTTGACTG 
Human A-garnma 茫?丨 n j j ene enhancer 
3 4 8 3 CTTATCTGTG GGGGAGGCTT TTGAAAAGTA ATTAGGTTTA GATGAGCTCA TAAGAGCAGA TCCCCATCAT AAAATTATTT 
GAATAGACAC CCCCTCCGAA AACTTTTCAT TAATCCAAAT CTACTCGAGT ATTCTCGTCT ftGGGGTAGTA TTTTAATAAA 
巧 ^ QHs enhancer 
3 5 6 3 TCCTTATCAG AAGCAGAGAG ACAAGCCATT TCTCTTTCCT CCCGGTGAGG ACACAGTGAG AAGTCCGCCA TCTGCAATCC 
AGGAATAGTC TTCGTCTCTC TGTTCGGTAA AGAGAAAGGA GGGCCACTCC TGTGTCACTC TTCAGGCGGT AGACGTTAGG 
Human A-gamma globin gene enhancer 
3 6 4 3 AGGAAGAGAA CCCTGACCAC GAGTCAGCCT TCAGAAATGT GAGAAAAAAC TCTGTTGTTG AAGCCACCCA GTCTTTTGTA 
TCCTTCTCTT GGGACTGGTG CTCAGTCGGA AGTCTTTACA CTCTTTTTTG AGACAACAAC TTCGGTGGGT CAGAAAACAT 
Human 今•gamma glpt^in 身 ? 二 
3 7 2 3 TTTTGTTATA GCACCTTGCA CTGAGTAAGG CAGATGAAGA AGGAGAAAAA AATAAGCTTG TCGACCGATG CCCTTGAGAG 
AAAACAATAT CGTGGAACGT G*^ 9;r，C;T;i;p；^ 了仁；“！；^：；！；？；！；了丁 TTATTCG/^C^,AGCTGGCTAC GGGAACTCTC 
MF1183 MF118 
3 8 0 3 CCTTCAACCC AGTCAGC 
GG^GTTGGG TCAGTCG 
MF1187 
Figure 3.8 Sequence Flanked by MF1186/MF1187 in pl224YAP-SEAP2-yAE. 
Endogenous SV40 enhancer located 3' downstream of SEAP gene in 
pSEAP-Enhancer was removed. Human A-gamma globin gene 3’ 




5995 AAACGAAACA AAACAAACTA GCAAAATAGG CTGTCCCCAG TGCAAGTGCA GGTGCCAGAA CATTTCTCTA TCGATAGGTA 
TTTGCTTTGT TTTGTTTGAT CGTTTTATCC GACAGGGGTC ACGTTCACGT CCACGGTCTT GTAAAGAGAT AGCTATCCAT 
Human A-gamma globin pens -754 promoter 
5 CTACATACAT ACCTGAATAT GGAATCAAAT ATTTTTCTAA GATGAAACAG TCATGATTTA TTTCAAATAG GTACGGATAA 
GATGTATGTA TGGACTTATA CCTTAGTTTA TAAAAAGATT CTACTTTGTC AGTACTAAAT AAAGTTTATC CATGCCTATT 
Human A-gamma ^^obin^ene -754 promoter 
8 5 GTAGATATTG AGGTAAGCAT TAGGTCTTAT ATTATGTAAC ACTAATCTAT TACTGCGCTG AAACTGTGGC TTTATAGAAA 
CATCTATAAC TCCATTCGTA ATCCAGAATA TAATACATTG TGATTAGATA ATGACGCGAC TTTGACACCG AAATATCTTT 
Human，炉Tyir|i丄伊？巧 :了?[ornoter 
1 6 5 TTGTTTTCAC TGCACTA7TG AGAAATTAAG AGATAATGGC AAAAGTCACA AAGAGTATAT TCAAAAAGAA GTATAGCACT 
AACAAAAGTG ACGTGATAAC TCTTTAATTC TCTATTACCG TTTTCAGTGT TTCTCATATA AGTTTTTCTT CATATCGTGA 
tHijn^�nj，m� g[，j? ge?e:了SieS^ mot气r 
2 4 5 TTTTCCTTAG AAACCACTGC TAACTGAAAG AGACTAAGAT TTGTCCCGTC AAAAATCCTG GACCTATGCC TAAAACACAT 
AAAAGGAATC TTTGGTGACG ATTGACTTTC TCTGATTCTA AACAGGGCAG TTTTTAGGAC CTGGATACGG ATTTTGTGTA 
MF1189 
Human A-gamma^ lob in^ene -754 promoter 
3 2 5 TTCACAATCC CTGAACTTTT CAAAAATTGG TACATGCTT1' AGCTTTAAAC TACAGGCCTC ACTGGAGCTA GAGACAAGAA 
AAGTGTTAGG GACTTGAAAA GTTTTTAACC ATGTACGAAA TCGAAATTTG ATGTCCGGAG TGACCTCGAT CTCTGTTCTT 
Iji^ man �:g?rptyi〒导[？巧 je?，:了promoter 
4 0 5 GGTAAAAAAC GGCTGACAAA AGAAGTCCTG GTATCCTCTA TGATGGGAGA AGGAAACTAG CTAAAGGGAA GAATAAATTA 
CCATTTTTTG CCGACTGTTT TCTTCAGGAC CATAGGAGAT ACTACCCTCT TCCTTTGATC GATTTCCCTT CTTATTTAAT 
Human 今 丄 罕 丨 ？ 巧 ge?e -754 promoter 
PspOMI 
4 8 5 GAGAAAAACT GGAATGACTG AATCGGAACA AGGCAAAGGC TATAAAAAAA ATTAGCAGTA TCCTCTTGGG GGCCCCTTCC 
CTCTTTTTGA CCTTACTGAC TTAGCCTTGT TCCGTTTCCG ATATTTTTTT TAATCGTCAT AGGAGAACCC CCGGGGAAGG 
I j i j巧 n 严ryirp〒穿丨〒力 gene :754 promot气r 
5 6 5 CCACACTATC TCAATGCAAA TATCTGTCTG AAACGGTCCC TGGCTAAACT CCACCCATGG GTTGGCCAGC CTTGCCTTGA 
GGTGTGATAG AGTTACGTTT ATAGACAGAC TTTGCCAGGG ACCGATTTGA GGTGGGTACC CAACCGGTCG GAACGGAACT 
6 4 5 CCAATAGCCT TGACAAGGCA AACTTGACCA ATAGTCTTAG AGTATCCAGT GAGGCCAGGG GCCGGCGGCT GGCTAGGGAT 
GGTTATCGGA ACTGTTCCGT TTGAACTGGT TATCAGAATC TCATAGGTCA CTCCGGTCCC CGGCCGCCGA CCGATCCCTA 
Human A-gamma globin gene -754 promoter 
7 2 5 GAAGAATAAA AGGAAGCACC CTTCAGCAGT TCCACACACT CGCTTCTGGA ACGTCTGAGG TTATCAAATC AAGCTTCGAA 
CTTCTTATTT TCCTTCGTGG GAAGTCGTCA AGGTGTGTGA ‘^^^g.巧巧 ‘*^“?‘呼^‘"^？^；“^‘々g^^yTAG TTCGAAGCTT 
MF1181 
SEAP 
8 0 5 TCGCGAATTC GCCCACCATG CTGCTGCTGC TGCTGCTGCT GGGCCTGAGG CTACAGCTCT CCCTGGGCAT CATCCCAGTT 
AGCGCTTAAG CGGGTGGTAC GACGACGACG ACGACGACGA CCCGGACTCC GATGTCGAGA GGGACCCGTA GTAGGGTCAA 
SEAP 
8 8 5 GAGGAGGAGA ACCCGGACTT CTGGAACCGC GAGGCAGCCG A 
CTCCTCCTCT TGGGCCTGAA GACCTTGGCG_ CTCCGTCGGC T 
MF1185 . 
Figure 3.9 Sequence Flanked by MF1184/MF1185 in P754YAP-SEAP2-YAE. A 
470-bp deletion was made at 5, end of A-gamma globin gene promoter 
region in pl224yAP-SEAP2-yAE to produce P754YAP-SEAP2-YAE. 
6 2 
MF1184 
5 4 4 6 AAACGAAACA AAACAAACTA GCAAAATAGG CTGTCCCCAG TGCAAGTGCA GGTGCCAGAA CATTTCTCTA TCGATAGGTA 
TTTGCTTTGT TTTGTTTGAT CGTTTTATCC GACAGGGGTC ACGTTCACGT CCACGGTCTT GTAAAGAGAT AGCTATCCAT 
Human A-^amma globin gene -205 promoter 
5 CGGCCCCTTC CCCACACTAT CTCAATGCAA ATATCTGTCT GAAACGGTCC CTGGCTAAAC TCCACCCATG GGTTGGCCAG 
GCCGGGGAAG GGGTGTGATA GAGTTACGTT TATAGACAGA CTTTGCCAGG GACCGRTTTG AGGTGGGTAC CCAACCGGTC 
Human A - ^ y i m a globin gene -205 promoter 
8 5 CCTTGCCTTG ACCAATAGCC TTGACAAGGC AAACTTGACC AATAGTCTTA GAGTATCCAG TGAGGCCAGG GGCCGGCGGC 
GGAACGGAAC TGGTTATCGG AACTGTTCCG TTTGAACTGG TTATCAGAAT CTCATAGGTC ACTCCGGTCC CCGGCCGCCG 
Human A-gamma globin gene -205 promoter 
1 6 5 TGGCTAGGGA TGAAGAATAA AAGGAAGCAC CCTTCAGCAG TTCCACACAC TCGCTTCTGG AACGTCTGAG GTTATCAAAT 
ACCGATCCCT ACTTCTTATT TTCCTTCGTG GGAAGTCGTC AAGGTGTGTG• AGCGAAGACC TTGCAGACTC C;^TAGTTTA 
MF1181 
SEAP 
2 4 5 CAAGCTTCGA ATCGCGAATT CGCCCACCAT GCTGCTGCTG CTGCTGCTGC TGGGCCTGAG GCTACAGCTC TCCCTGGGCA 
GTTCGAAGCT TAGCGCTTAA GCGGGTGGTA CGACGACGAC GACGACGACG ACCCGGACTC CGATGTCGAG AGGGACCCGT 
SEAP 
3 2 5 TCATCCCAGT TGAGGAGGAG AACCCGGACT TCTGGAACCG CGAGGCAGCC GA 
AGTAGGGTCA ACTCCTCCTC TTGGGCCTGA AGACg^^yqgc; gqyqgqyqgq—g"^ 
MF1185 
Figure 3.10 Sequence Flanked by MF1184/MF1185 in plOSyAP-SEAPl-yAE. A 
1019-bp deletion was made at 5' end of A-gamma globin gene promoter 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































In this part of the project, the aim was to produce promoter-reporter plasmid 
constructs with partially truncated promoter forms to facilitate LC978-responsive 
elements mapping in the following part of study. 
The promoter region ranging from -1224 to +30 of human A gamma globin gene 
transcription initiation site was chosen to be the focus of study. Though there were 
series of previous studies suggesting that minimal promoters of gamma globin genes 
were resided within -202 from the transcription initiation sites (McCaffrey et al, 
1997; Ikuta et al., 1998), there were also reports evidencing that 5' flanking sequence 
exceeding this range could be responsive to pharmaceutical agents such as arginine 
butyrate, sodium butyrate, trapoxin and trichostatin in gamma globin gene 
reactivation (McCaffrey et al., 1997; Pace et al., 2000). For a newly discovered 
pharmaceutical agent LC978, there was no clue about which part of the promoter nor 
which of the two promoters could it be acting on during the drug-induced gamma 
globin gene reactivation. As a pioneer promoter regulation study for LC978, 
choosing -1224 region of A gamma globin was a logical consequence of several 
considerations. It was hypothesized that -1224 region should have high chance in 
including all potentially inducible elements of the gamma globin gene promoter, as 
the furthest inducible element reported so far was at -822 till -893 by sodium 
butyrate (Pace et al., 2000). To include the A gamma globin gene 3' enhancer in all 
promoter-reporter constructs was aimed to increase the basal as well as induced 
reporter gene expression level, so as to facilitate reporter quantification. 
Choosing secretary alkaline phosphatase (SEAP) as the reporter gene for plasmid 
constructions in this study was a result of several considerations. SEAP was first 
introduced in 1988 as a candidate reporter gene (Berger et al, 1988). Since then, a 
number of methods was developed for quantitative assay of the reporter (Cullen & 
67 
Malim, 1992; Bronstein et al., 1994). SEAP was recognized as a powerful reporter 
gene that facilitate sensitive yet accurate measurement of the gene product at mRNA 
or protein level, which suggested that SEAP may serve as a good reporter in 
promoter-reporter assays where measurement of minute change in reporter 
expression is required. Another consideration was the background signal issue. In 
general consideration, it is believed that a high signal-to-background ratio of a 
reporter is favorable to enhancing sensitivity of measurement. It was found that K562 
cell line does not produce alkaline phosphatase itself (Lozzio & Lozzio, 1975). So, it 
is expected that applying SEAP as reporter for K562 transient transfection 
experiments would encounter no problem on signal interference from endogenous 
alkaline phosphatase expression. Also, SEAP reporter is a heat stable enzyme, in 
which it retains its activity after a heat inactivation process that involves incubation 
at 65°C. This inactivation procedure can effectively eliminate other phosphatases that 
may interfere signal detection. The last consideration was on the practical side of the 
experiment. SEAP is a secretary protein, which the quantitation of the reporter can be 
performed by retrieving culture medium of the transiently transfected cells. This 
facilitates smooth experimental procedures when the transfected cells themselves 
were required for assays of intracellular proteins such as fetal hemoglobin or 
transfection normalization standard sourcing from the same experimental setup. 
To conclude, three plasmid constructs were produced in this part, and were annotated 
P1224YAP-SEAP2-yAE, p754yAP-SEAP2-7AE and p205yAP-SEAP2-yAE for 
human A gamma globin gene -1224, -754 and -205 promoter respectively. All of 
these constructs identically harbor a SEAP reporter gene and a human A gamma 
globin gene 3' enhancer downstream to the reporter gene, driven by various lengths 
of the human A gamma globin gene promoter. They were used for LC978-responsive 
elements mapping in the following chapter. 
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Chapter 4 Mapping of LC978-Responsive Elements on Human 
A-Gamma Globin Gene Promoter 
4.1 Promoter Deletion Analysis 
In order to identify LC978-responsive elements in -1224 5, flanking fragment of 
human A gamma globin gene promoter, the full -1224 promoter region was cloned, 
and promoter deletions were made at -754 and -205 upstream of the flanking 
sequence. Three plasmid constructs with SEAP reporter gene driven by each of these 
promoters were built as described in Chapter 3. These plasmid constructs were 
transiently transfected into K562 cell line, and the corresponding expressions of 
SEAP reporter gene were quantified by reporter chemiluminescence assay (Bronstein 
et al., 1994) upon induction by LC978. Assays were performed using SEAP reporter 
gene assay kit from Roche Applied Science based on CSPD substrate. The substrate 
can be readily dephosphorylated by alkaline phosphatase to result in decomposition 
of the unstable dioxetane ion and emit light with emission peak at wavelength of 
477nm. Investigation on inducibility of each truncated promoter by LC978 was the 
aim of this study. It was expected that a deletion of important regulatory sequence 
that is specifically responsive to LC978 would result in a decrease in promoter 
activity upon LC978 induction, and thus decreased reporter expression level. In the 
experiment, activity of the endogenous A gamma globin gene promoter was also 
monitored by measuring fetal hemoglobin expression level using fetal hemoglobin 
quantitation ELISA. 
4.2 pSV-p-Galactosidase as a Transfection Variations Normalization Standard 
pSV-P-Galactosidase (pSV-p-Gal; GenBank: X65335) was also included as transient 
transfection internal normalization control for variations in transfection efficiencies. 
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pSV-(3-Gal vector carries a recombinant bacterial lacZ gene driven by SV40 early 
promoter and enhancer linked upstream to the gene. When transfected into 
mammalian cells, the gene will be constitutively transcribed (Hall et al., 1983). The 
gene, when transcribed and translated, produces a gene product that is the 
p-galactosidase enzyme. The reporter gene product can be quantified from cell 
lysates using spectrophotometric (Lim & Chae, 1989), fluorescent or 
chemiluminescent assays (Silhavy et al., 1984; Schenbom & Groskreutz, 1999) 
dependent on which substrate to be used. In this study, pSV-P-Gal was co-transfected 
together with each of three promoter-reporter constructs as an internal control for 
variations in transfection efficiencies. Expression level of p-galactosidase enzyme 
was assayed by Promega p-galactosidase enzyme assay system based on ONPG 
substrate. The colourless substrate can be hydrolyzed to form yellow o-nitrophenol 
with absorption peak at wavelength of 420nm, the colour intensity was then 
measured by spectrophotometric analysis. 
4.3 Experimental Strategy 
The first part of the study was aimed at determining the optimal dose of transfection 
reagent for maximal transient expression in K562 cell line. Briefly, pEGFP-Nl 
vector (GenBank: U55762) which harbor an enhanced green fluorescent protein 
(EGFP) gene driven by constitutive human cytomegalovirus (CMV) promoter was 
transiently transfected into K562 cells using different volumes of DMRIE-C 
transfection reagent. The optimal dose of transfection reagent was determined by the 
volume that gave the highest EGFP expression level. The second part of the study 
focused on investigating the background signal of P-galactosidase in K562 cell line 
when pSV-p-Gal was transiently transfected into the cells using an optimal dose of 
transfection reagent determined from the previous part. Final part of the study 
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investigated the inducibility of various lengths of human A gamma globin gene 
promoter by LC978. Briefly, pSV-p-Gal together with p 1 224YAP-SEAP2-YAE, 
p754YAP-SEAP2-yAE or p205yAP-SEAP2-yAE were co-transfected into K562 cells. 
The dual-vector co-transfected cells were then induced by LC978. Changes in level 
of SEAP reporter expression were measured and were normalized to p-galactosidase 
level. Fetal hemoglobin expression level was also monitored by HbF quantitation 
ELISA so as to act as a proof of positive pharmaceutical induction upon transfection. 
As controls, drug-induced SEAP expressions on K562 cells co-transfected with 
promoter-reporter constructs were also tested using fetal hemoglobin inducing agents 




4.4.1 Chemicals, Kits and Reagents 
Item Name and Description Manufacturer / Cat. No. 
3,3',5,5'-Tetramethylbenzidine (TMB) Sigma T2885 
31-33% Hydrochloric acid (HCl) BDH 10307 
Acetic acid, glacial BDH 100015N 
Antibiotic-Antimycotic (PSF, 1 OOX), liquid Invitrogen 15240-062 
P-Galactosidase Enzyme Assay System with Reporter Promega E2000 
Lysis Buffer 
Bovine Serum Albumin (BSA), Cohn Fraction V Invitrogen 11018-017 
Citric acid monohydrate UNIVAR 160 
Dimethyl sulfoxide (DMSO) Fisher D/4121/PB 17 
DMRIE-C Transfection Reagent Invitrogen 10459-014 
Dulbecco's Phosphate-Buffered Saline (D-PBS), powder Invitrogen 21600-010 
Ethanol, absolute Merck 1.00983.2511 
Fetal Bovine Serum (FBS), Certified Invitrogen 16000-069 
Hemoglobin A2, ferrous stabilized human Sigma H0266 
Human Hemoglobin F (HbF) ELISA Quantitation Kit Bethyl Labs E80-136 
Sheep anti-Human HbF Ab, affinity purified Bethyl Labs A80-136A 
Sheep anti-Human HbF Ab, peroxidase-conjugated Bethyl Labs A80-136P 
HbF Calibrator Bethyl Labs RC80-135-4 
Hydrogen peroxide (H2O2, 30% v/v solution) BDH 101284N 
LC978 Solution * 
RPMI Medium 1640, powder Contains L-glutamine and 25 Invitrogen 23400-021 
mM HEPES buffer, but no sodium bicarbonate 
SEAP Reporter Gene Assay, chemiluminescent Roche 11779842001 
Sodium bicarbonate (NaHCOs) Sigma S5761/S8875 
Sodium butyrate Sigma B5887 
Sodium carbonate anhydrous (NazCOs) BDH 102404H 
Sodium chloride (NaCl) Sigma S3014 
Sodium hydroxide (NaOH) Sigma S5881 
Sodium phosphate monobasic anhydrous (NaHsPCU) Sigma S0751 
iQTM SYBR® Green Supermix Bio-Rad 170-8880 
Tris base NH2C(CH20H)3 USB 75825 
Tween 20 USB 20605 
Triton X-100 Fluka 93426 * 
Kindly provided by Dr. Fung's graduate student Dr. Eric Xing. 
72 
4.4.2 Buffers and Solutions 
Item Name Item Description 
Complete RPMI 1640 One package of RPMI Medium 1640 and 2.0g sodium 
Medium bicarbonate was dissolved in 950ml Milli-Q H2O, pH was 
adjusted to pH 7.2 with IM NaOH. Final volume was 
topped up to IL by Milli-Q H2O. Resulting solution was 
filtered through 0.22|j.m membrane filter under sterile 
condition. Complete RPMI 1640 medium was made by 
supplementing with 10% FCS (v/v) and 1% PSF (v/v). 
ELISA Blocking Solution 1% BSA (w/v) in IX TBS, freshly prepared 
ELISA Cell Lysis Buffer 1% Triton X-100 in IX TBS, freshly prepared 
ELISA Coating Buffer 50mM carbonate-bicarbonate at pH 9.6. 0.0795g NaiCOs 
and 0.357g NaHCOs were dissolved in 100ml Milli-Q 
H2O. Solution was stored at 4°C until use. 
ELISA Wash Solution 0.05% Tween 20 (v/v) in IX TBS, freshly prepared 
ELISA Sample Diluent 0.25% Tween 20 (v/v) and 1% BSA (w/v) in IX TBS, 
freshly prepared 
ELISA TMB Stock 5mg/ml TMB in DMSO, stored in airtight glass tube in 
Solution dark at room temperature 
ELISA TMB Substrate 2.555g citric acid and 3.095g NaH2P04 were dissolved in 
Buffer 200ml Milli-Q H2O, pH was adjusted to pH 5.5 with 5M 
NaOH. Final volume was topped up to 250ml by Milli-Q 
H2O. Solution was stored at 4°C until use. 
LC978 Working Solution 10|ig/ml LC978 in sterile RPMI 1640 medium 
Phosphate Buffered One package of Dulbecco's Phosphate-Buffered Saline 
Saline (PBS) (D-PBS) was dissolved in IL Milli-Q H2O. Solution was 
sterilized by autoclave at 121°C for 20 mins. 
Tris Buffered Saline 50mM Tris and 140mM NaCl at pH 8.0 
(TBS) 
TMB Stock Solution 5mg/ml TMB in glacial acetic acid 
TMB Working Buffer 5.1 Ig citric acid and 6.19g NaH2P04 were dissolved in 
450ml Milli-Q H2O, pH was adjusted to pH 5.0 with 5M 
NaOH. Final volume was topped up to 500ml by Milli-Q 
H2O. Solution was stored at 4°C until use. 
TMB Working Solution Freshly prepared by mixing 19.8ml TMB working buffer, 
200|il TMB stock solution and 400|al 30% H2O2. 
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4.4.3 Cell Line 
Item Name and Description Manufacturer / Cat. No. 
K562 ATCC® CCL-243™ 
The human myeloid leukemia cell line K562 was purchased from ATCC®. The 
K562 cells were cultured in complete RPMI 1640 medium. The cultures were 
maintained under a humidified atmosphere with 95% air / 5% CO2 at 37�C, with cell 
density not exceeding 3x10^ cells/ml. 
4.4.4 Nucleic Acids 
Item Name and Description Manufacturer / Cat. No. 
dNTP Set, 1 OOmM Solutions Amersham 27-2035-02 
pd(T)i2-i8 Amersham 27-7858-01 
pEGFP-Nl (GenBank: U55762) Clontech 6085-1 
pSEAP2-Enhancer (GenBank: U89939) Clontech 6051-1* 
pSV-P-Galactosidase (GenBank: X65335) Promega ElOSl* 
* Kindly provided by Dr. Ge's graduate student Ms. Lin Sze-wah. 
4.4.5 Equipments 
Item Name and Description Manufacturer / Cat. No. 
96 MicroWellTM plates Nunclon™A, Round Bottom, Nunc™ 163320 
Polystyrene, Sterile 
96 MicroWellTM Plates Nunclon™A, Flat Bottom, Nunc™ 167008 
Polystyrene, Sterile 
96 Well Clear Flat Bottom Polystyrene High Bind Coming® 9018 
Microplate 
4.5 Methods 
4.5.1 Determination of Optimal Dose of Transfection Reagent for K562 
a) Sterilization of Plasmid DNA for Transfection 
pEGFP-N 1 plasmid DNA was isolated from E. coli DH5a according to Section 
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3.6.1(h). The plasmid DNA was then sterilized by ethanol precipitation as in Section 
3.6.1(c). 70% ethanol wash upon last step in ethanol precipitation was discarded and 
the DNA pellet was air-dried under sterile condition. DNA pellet was then 
re-dissolved in sterilized Milli-Q H2O. Aliquot of the sterilized DNA solution was 
used for quantitation by spectrophotometric analysis. Resulting sterilized DNA 
solution was used for transfection. 
b) Transient Transfection of K562 Cells by pEGFP-Nl 
4\ig pEGFP-Nl was mixed either with 2|il, 4iil, 6^1, 8|il or 12^1 DMRIE-C 
transfection reagent in 1ml serum-free RPMI (sfRPMI) 1640 medium in each well of 
a 6-well tissue culture plate. The DMRIE-C/DNA mixtures in sfRPMI 1640 medium 
were mixed well by gentle agitation, and were allowed to incubate at room 
temperature for 30-40 minutes for formation of DMRIE-C/DNA complex. 
K562 cell line propagated under passage with cell density maintained under 3 x 
1 c e l l s / m l was determined for its cell density by trypan blue exclusion counting on 
a hemocytometer under an inverted light microscope. Cells required for six 
transfections (i.e. 2 x 1 0 ^ cells/transfection) were pellet by centrifugation at 300r.c.f. 
for 10 minutes and supernatant was discarded. The cell pellet was then washed once 
with 20ml sfRPMI 1640 medium. Supernatant was carefully removed without 
dislodging cells. The washed cell pellet was then resuspended in sfRPMI 1640 at 1 x 
10^ cells/ml. 200|j.l (i.e. 2 x 1 0 ^ cells) of the cell suspension was then added to each 
well of the plate containing DMRIE-C/DNA complex. The plate was incubated in a 
humidified incubator at 37°C with 5% CO2 for five hours. Upon the end of 
incubation, 2ml RPMI 1640 medium with 15% FBS (without antibiotics) was added 
to each well of the plate. Incubation continued at 37°C / 5% CO2 for 48 hours. 
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c) Examination of EGFP Expression Level 
K562 cells at the 48出 hour post-transfection were observed under an inverted light 
microscope (Nikon Eclipse TS-IOOF) and photomicrographs were recorded using 
lOX objective by a charge-coupled device (CCD) camera connected to the 
microscope. K562 cells morphologies were captured under bright light, with 
exposure duration of 1/11 sees. EGFP expressed by K562 cells was excited by blue 
laser at 488nm wavelength, and corresponding fluorescent images were captured at 
exposure duration of 11.31 sees. 
4.5.2 p-Galactosidase as Normalization Control for K562 Transfections 
a) Transient Transfection of K562 Cells by pSV-p-Gal 
Sterilized pSV-P-Gal plasmid DNA solution was prepared as in Section 4.5.1(a). 2 x 
106 K562 cells were transfected with or without 4|xg pSV-(3-gal by 8|il DMRIE-C (i.e. 
determined from Section 4.5.1) in each well of a 6-well tissue culture plate as in 
Section 4.5.1(b). The plate was incubated in a humidified incubator at 37°C with 5% 
CO2 for 48 hours. 
b) Determination of p-Galactosidase Expression Level 
P-galactosidase expressed by pSV-(3-Gal-transfected K562 cells was quantified by 
Promega p-galactosidase Enzyme Assay System. Briefly, K562 cells at the hour 
post-transfection were resuspended by pipetting ups and downs. Cells in each of the 
cell suspensions were then pelleted in 1.8-ml centrifuge tube by centrifugation at 
300r.c.f. for 10 minutes. Each cell pellet was washed twice with 1ml pre-cooled PBS. 
Supernatant after final wash was carefully removed without dislodging cells. 175|il 
IX Reporter Lysis Buffer (from Promega E2000 Assay Kit) was then added to each 
of the tubes. The tubes were incubated at ice for 15 minutes with brief vortex at 
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5-min interval. The cell lysates were then centrifuged at 16k r.c.f. for two minutes at 
4°C. 50|il of each supernatant was transferred to each well of a flat-bottom 96-well 
culture plate. 50|il pre-warmed Assay 2X Buffer was added to each of the wells, and 
was mixed by gentle agitation of the plate. The 96-well plate was wrapped with 
laboratory parafilm and was incubated at 37°C for three hours. At the end of 
incubation, 150|J1 1M Sodium Carbonate was added to each of the wells to stop the 
reaction. The yellow colour developed was then quantified by measuring optical 
density at 420nm wavelength (OD420) by SpectraMAX 250 microplate 
spectrophotometer. 
4.5.3 Mapping of LC978-Responsive Elements on Human Gamma Globin 
Gene Promoter 
a) Co-Transfection of K562 Cells by pl224/754/205YAP-SEAP2-7AE and 
pSV-p-Gal 
Sterilized p 1224yAP-SEAP2-yAE, P754YAP-SEAP2-YAE and 
plOSyAP-SEAPl-yAE plasmid DNA solution was prepared as in Section 4.5.1(a). 
Each of 2 X 10^ K562 cells were co-transfected with 2|ig p 1224yAP-SEAP2-YAE, 
P754YAP-SEAP2-YAE or p205yAP-SEAP2-YAE together with 2\xg pSV-|3-gal in 
each well of a 6-well tissue culture plate as in Section 4.5.1(b). The plate was 
incubated in a humidified incubator at 37°C with 5% CO2. 
b) Treatment of Co-Transfected K562 Cells by LC978 
At 24^ hour post-transfection, K562 cells were treated by 3.125ng/ml LC978 at 
initial cell density at 1 x cells/ml. Briefly，0.4ml of each of the transfected K562 
cell populations prepared from Section 4.5.3(a) was diluted at 1:4 in complete RPMI 
1640 medium (i.e. v/v; 0.4ml cells + 1.6ml medium), and the viable cell density in 
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the diluted cell suspensions were determined by trypan blue exclusion counting on a 
hemocytometer. Cell suspensions were then further diluted to 2 x cells/ml in 
complete RPMI 1640 medium, and 0.5ml of each diluted cell suspensions was 
transferred to each well of a 24-well tissue culture plate. LC978 was diluted to 
6.25ng/ml in complete RPMI 1640 medium. 0.5ml of the diluted LC978 was mixed 
with cell suspensions in each well of the 24-well tissue culture plate. All treatment 
and non-treatment groups were performed in triplicates, and the plate was incubated 
at 37°C with 5% CO2 for 3.5 days. 
c) Determination of p-Galactosidase Expression Level 
At 48th hour post-transfection, 3ml of each co-transfected K562 cell population 
prepared from Section 4.5.3(a) was collected in 1.8-ml centrifuge tube, 
p-galactosidase expressed by pSV-P-Gal and p 1224/754/205yAP-SEAP2-yAE 
co-transfected K562 cells was quantified by Promega p-galactosidase Enzyme Assay 
System as described in Section 4.5.2(b). 
d) Determination of Secreted Alkaline Phosphatase (SEAP) Expression Level 
K562 cells co-transfected with P1224/754/205YAP-SEAP2-YAE and pSV-p-Gal were 
assayed for SEAP expression level at S.S'*^  day post LC978 treatment. Assay was 
performed based on quantitative analysis using SEAP Reporter Gene Assay 
(Chemiluminescent) Kit. 
At 3.5th day post LC978 treatment, 800|il of each of K562 cell suspensions in the 
24-well tissue culture plate prepared from Section 4.5.3(b) was transferred to 1.8-ml 
centrifuge tube, and 200|il of each suspension was reserved for further HbF content 
determination. The tubes were centrifuged at 300r.c.f. for 10 minutes to pellet the 
cells. Supernatants were transferred to new 1.8-ml centrifuge tubes. Each of the clear 
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supematants was diluted at 1:1 in Dilution Buffer (from SEAP Reporter Gene Assay 
Kit, Roche Applied Science) in 1.8-ml centrifuge tube. Diluted samples were mixed 
well by vortex, spun-down and were incubated at 65°C in a thermomixer for 30 
minutes to inactivate heat-unstable endogenous alkaline phosphatase. 
Heat-inactivated samples were quickly chilled on ice for five minutes, and then were 
centrifuged at 16k r.c.f. for one minutes to pellet any debris. 20|xl of each 
heat-inactivated samples was mixed with 20|il Inactivation Buffer in each well of a 
white 96-well plate. The plate was incubated at room temperature for five minutes. 
Then, 20|J.1 freshly prepared Substrate Reagent was added to each well containing the 
diluted sample, and the plate was incubated at room temperature for 10 minutes. 
After incubation, chemiluminescence signals were captured and measured by Roche 
Lumi-Imager Fl , where the chemiluminescence intensities were quantified and 
analyzed by LumiAnalyst software. 
e) Determination of Fetal Hemoglobin Expression Level 
K562 cells co-transfected with pl224/754/205yAP-SEAP2-yAE and pSV-P-Gal were 
assayed for fetal hemoglobin expression level at 3.5^ day post LC978 treatment. 
Assay was performed based on HbF ELISA Quantitation Kit as described in Section 
2.4.2. Briefly, at 3.5'^ day post LC978 treatment, 200|il of each of K562 cell 
suspensions in the 24-well tissue culture plate prepared from Section 4.5.3(b) was 
transferred to each well of a 96-well round bottom plate. The plate was then 
centrifuged at 300r.c.f. for 10 minutes and the supematants were carefully aspirated 
with the aid of a 200|il pipette tip connected to a peristaltic pump. Cell pellet in each 
well was lysed with 20|il cell lysis buffer as described in Section 2.4.2(c), where 
subsequent procedures for antigen capture and signal development were same as 
described. 
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4.5.4 Mapping of Hydroxyurea-Responsive Elements on Human Gamma 
Globin Gene Promoter 
a) Determination of Optimal Biological Dose (OBD) of Hydroxyurea 
Optimal biological dose (OBD) of hydroxyurea on K562 cells with regard to 
induction for hemoglobin expression was determined by in vitro bioassay for total 
hemoglobin production as described in Section Section 2.4.1. Briefly, hydroxyurea 
stock solution (i.e. 50mg/ml) was diluted to 200|ig/ml in complete RPMI 1640 
medium. 200|j.l of the diluted hydroxyurea was transferred to first well of a row of 
96-well round bottom cell culture plate. Subsequent serial two-fold dilutions were 
made in 1 OOjxl complete RPMI 1640 medium across each well of the row until a final 
of 1/2048 dilution was made in the last (12【卜）well. K562 cells propagated under 
passage with cell density maintained below 3 x 10^  cells/ml was diluted to 2 x lO. 
cells/ml in complete RPMI 1640 medium. 100|j,l of the diluted cells were then added 
to each well containing various concentrations of diluted hydroxyurea. The plate was 
incubated in a humidified incubator at 37°C with 5% CO2 for eight days, then the 
total hemoglobin produced by K562 cells were assayed as described in 2.4.1. 
b) Co-Transfection of K562 Cells and Subsequent Treatment by Hydroxyurea 
K562 cells were co-transfected by pl224yAP-SEAP2-YAE, p754yAP-SEAP2-yAE or 
p205YAP-SEAP2-yAE together with pSV-P-gal as described in Section 4.5.3(a). The 
prepared 6-well tissue culture plate containing the cells was then incubated in a 
humidified incubator at 37°C with 5% CO2. At hour post-transfection, K562 
cells were treated by 25|ig/ml hydroxyurea [i.e. OBD determined from Section 
4.5.4(a)] at initial cell density at 1 x lO* cells/ml as described in Section 4.5.3(b). 
Briefly, each of the transfected K562 cell populations was diluted at 1:4 in complete 
RPMI 1640 medium (i.e. v/v; 0.4ml cells + 1.6ml medium), and the viable cell 
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density in the diluted cell suspensions were determined by trypan blue exclusion 
counting on a hemocytometer. Cell suspensions were then further diluted to 2 x 1O* 
cells/ml in complete RPMI 1640 medium, and 0.5ml of each diluted cell suspensions 
was transferred to each well of a 24-well tissue culture plate. Hydroxyurea was 
diluted to 50ng/ml in complete RPMI 1640 medium. 0.5ml of the diluted 
hydroxyurea was mixed with cell suspensions in each well of the 24-well tissue 
culture plate. The plate was incubated at 37°C with 5% CO2 for 3.5 days. 
c) Assay for p-Galactosidase (p-Gal), Secreted Alkaline Phosphatase (SEAP) 
and Fetal Hemoglobin (HbF) Expression Level 
Co-transfected K562 cell populations were assayed for P-Gal expression level by 
Promega P-galactosidase Enzyme Assay System at 48th post-transfection as 
described in Section 4.5.3(c). The SEAP and HbF expression levels of 
hydroxyurea-treated and dual vectors co-transfected K562 cell populations were 
assayed by SEAP Reporter Gene Assay (Chemiluminescent) Kit and HbF ELISA 
Quantitation Kit respectively at day post hydroxyurea treatment, as described in 
Section 4.5.3(d) and 4.5.3(e). 
4.5.5 Sodium Butyrate-Induced SEAP Expression 
a) Determination of Optimal Biological Dose (OBD) of Sodium Butyrate 
Optimal biological dose (OBD) of sodium butyrate on K562 cells with regard to 
induction for fetal hemoglobin expression was determined by in vitro bioassay for 
fetal hemoglobin production as described in Section 2.4.2. Briefly, sodium butyrate 
stock solution (i.e. 200mM) was diluted to 40mM in complete RPMI 1640 medium. 
200|il of the diluted sodium butyrate was transferred to first well of a row of 96-well 
round bottom cell culture plate. Subsequent serial two-fold dilutions were made in 
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100|il complete RPMI 1640 medium across each well of the row until a final of 
1/2048 dilution was made in the last (12^ )^ well. K562 cells propagated under 
passage with cell density maintained below 3 x 10^  cells/ml was diluted to 2 x lO* 
cells/ml in complete RPMI 1640 medium. 100|xl of the diluted cells were then added 
to each well containing various concentrations of diluted sodium butyrate. The plate 
was incubated in a humidified incubator at 37°C with 5% CO2 for eight days, then 
the fetal hemoglobin produced by K562 cells were assayed by HbF ELISA 
Quantitation Kit as described in 2.4.2(b)(c) and (d). 
b) Co-Transfection of K562 Cells and Treatment by Sodium Butyrate 
K562 cells were co-transfected by pi224yAP-SEAP2-yAE, p754yAP-SEAP2-yAE or 
P205YAP-SEAP2-YAE together with pSV-(3-gal as described in Section 4.5.3(a). The 
prepared 6-well tissue culture plate containing the cells was then incubated in a 
humidified incubator at 37°C with 5% CO2. At hour post-transfection, K562 
cells were treated by 312.5|a.M sodium butyrate [i.e. OBD determined from Section 
4.5.5(a)] at initial cell density at 1 x cells/ml as described in Section 4.5.3(b). 
Briefly, each of the transfected K562 cell populations was diluted at 1:4 in complete 
RPMI 1640 medium (i.e. v/v; 0.4ml cells + 1.6ml medium), and the viable cell 
density in the diluted cell suspensions were determined by trypan blue exclusion 
counting on a hemocytometer. Cell suspensions were then further diluted to 2 x 1O^  
cells/ml in complete RPMI 1640 medium, and 0.5ml of each diluted cell suspensions 
was transferred to each well of a 24-well tissue culture plate. Sodium butyrate was 
diluted to 625}iM in complete RPMI 1640 medium. 0.5ml of the diluted sodium 
butyrate was mixed with cell suspensions in each well of the 24-well tissue culture 
plate. The plate was incubated at 37°C with 5% CO2 for 3.5 days. 
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c) Assay for p-Galactosidase (p-Gal)，Secreted Alkaline Phosphatase (SEAP) 
and Fetal Hemoglobin (HbF) Expression Level 
Co-transfected K562 cell populations were assayed for P-Gal expression level by 
Promega P-galactosidase Enzyme Assay System at 48 post-transfection as described 
in Section 4.5.3(c). The SEAP and HbF expression levels of sodium butyrate-treated 
and dual vectors co-transfected K562 cell populations were assayed by SEAP 
Reporter Gene Assay (Chemiluminescent) Kit and HbF ELISA Quantitation Kit 
respectively at day post sodium butyrate treatment, as described in Section 
4.5.3(d) and 4.5.3(e). 
4.5.6 Data Analysis 
a) Data Processing, Normalization and Graphing 
Experimental data from p-galactosidase enzyme assay and SEAP reporter gene assay 
was processed by GraphPad Prism® software. Transfection normalization was done 
by dividing the Biochemical Light Unit (BLU) reading of SEAP chemiluminescence 
by OD420 from the corresponding p-galactosidase assay of the transfection set: 
_ Signal from SEAP Assay BLU - Blank 
Normalized SEAP Activity = Signal from p-gal Assay 二 Mean (OD420 - Blank) 
Graphs were plotted with all values expressed in Mean 士 Standard Error of the Mean 
(SEM). 
b) Statistical Analysis 
Normalized data from Section 4.5.6(b) was analyzed by two-way analysis of 
variance (ANOVA) in GraphPad Prism® software followed by Bonferroni post-tests 




4.6.1 Optimal Dose of Transfection Reagent for K562 
K562 cells were transiently transfected by 4|ig pEGFP-Nl plasmid DNA with 
various amount of DMRIE-C reagent ranging from 0|j.l to 12|j.l. With regard to 
fluorescence emitted by green fluorescent protein (GFP) under excitation of 488nm 
laser, the most optimal condition (i.e. optimal dose of DMRIE-C reagent) was 
determined by the set of transfection that gave the most fluorescent cells. From the 
result (Figure 4.1), it was determined that 8|il DMRIE-C reagent was optimal for 
transfection of K562 cells in each well of a 6-well tissue culture plate. 
4.6.2 p-Galactosidase as Normalization Standard for K562 Transfections 
K562 cells were transiently transfected by 4|ig pSV-p-gal plasmid DNA, with 8|j,l 
DMRIE-C-only and DNA/DMRIE-C-absent sets as negative controls. This was to 
investigate whether or not the DMRIE-C reagent would interfere the results obtained 
from P-galactosidase enzyme assay system. From the result (Figure 4.2), it was 
found that only the pSV-p-gal transfected K562 cells showed a significant difference 
to negative control, with no significant difference between the DMRIE-C set and the 
negative control. It was believed that pSV-p-gal plasmid DNA and the corresponding 
enzyme assay system was applicable to normalizations of K562 cells transfection 
experiments. 
4.6.3 LC978 Induction on Co-Transfected K562 Cells 
Four groups of K562 cells co-transfected by promoter-reporter vectors and 
normalization vector were assayed for fetal hemoglobin production by HbF ELISA 
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Quantitation Kit after treatment with LC978. From the result (Figure 4.3), it was 
found that for each of four transfection groups, there was a significant increase of 
fetal hemoglobin production upon treatment by 3.125ng/ml LC978. 
Four co-transfected groups of cells were also assayed for SEAP reporter activity 
upon LC978 treatment (Figure 4.4). For promoter-less construct, there was found to 
be no significant difference between treated and un-treated groups, with their SEAP 
activities both resided at minima among all groups in the entire test. On the other 
hand, each group of cells that was transfected with reporter construct driven either by 
human A-gamma globin gene -1224, -754 or 一205 promoter showed significant 
decrease upon treatment by 3.125ng/ml LC978. 
Basal expression level of SEAP for reporter construct driven by -754 promoter was 
found to be highest, with that of -205 promoter slightly lower and -1224 promoter 
found to be the lowest. 
4.6.4 Hydroxyurea Induction on Co-Transfected K562 Cells 
Optimal dose of hydroxyurea treatment on K562 in term of hemoglobin production 
was determined by in vitro bioassay for hemoglobin production as described in 
Section 4.5.4(a). From the result (Figure 4.5), it was determined that hydroxyurea at 
25}j.g/ml induced the highest level of total hemoglobin on K562 cells. 
Four groups of K562 cells co-transfected by promoter-reporter vectors and 
normalization vector were assayed for fetal hemoglobin production by HbF ELISA 
Quantitation Kit after treatment with hydroxyurea. From the result (Figure 4.6), it 
was found that for each of four transfection groups, there was a significant increase 
of fetal hemoglobin production upon treatment by 25|4.g/ml hydroxyurea. 
Four co-transfected groups of cells were also assayed for SEAP reporter activity 
upon hydroxyurea treatment (Figure 4.7). For promoter-less construct, there was 
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found to be no significant difference between treated and un-treated groups, with 
their SEAP activities both resided at minima among all groups in the entire test. The 
construct driven by human A gamma globin gene -1224 promoter also showed no 
significant difference between treated and un-treated groups on SEAP expression 
level, while their basal levels were significantly higher than that of promoter-less 
construct. Each group of cells that was transfected with reporter construct driven 
either by human A-gamma globin gene -754 or -205 promoter showed significant 
decrease upon treatment by 25 jig/ml hydroxyurea. Pattern of basal expression levels 
for all three SEAP reporter constructs were found to resemble that observed for 
LC978 (Section 4.6.3) experiment. 
4.6.5 Sodium Butyrate Induction on Co-Transfected K562 Cells 
Optimal dose of sodium butyrate treatment on K562 in term of fetal hemoglobin 
production was determined by HbF quantitation ELISA as described in Section 
4.5.5(a). From the result (Figure 4.8), it was determined that sodium butyrate at 
312.5 jiM induced the highest level of fetal hemoglobin on K562 cells. 
Four groups of K562 cells co-transfected by promoter-reporter vectors and 
normalization vector were assayed for fetal hemoglobin production by HbF ELISA 
Quantitation Kit after treatment with sodium butyrate. From the result (Figure 4.9), it 
was found that there was increased fetal hemoglobin production upon butyrate 
treatment for each of four transfection groups. After statistical analysis by two-way 
AN OVA and Bonferroni post-tests, it was determined that the differences between 
treated and un-treated groups in -754 and -205 promoter construct transfected 
groups were statistically significant. On the other hand, those of promoter-less 
and -1224 promoter construct were determined to be not statistically significant. 
Four co-transfected groups of cells were also assayed for SEAP reporter activity 
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upon sodium butyrate treatment (Figure 4.10). For promoter-less construct, there was 
found to be no significant difference between treated and un-treated groups, with 
their SEAP activities both resided at minima among all groups in the entire test. Each 
group of cells that was transfected with reporter construct driven either by human 
A-gamma globin gene -1224, -754 or -205 promoter showed significant increase 
upon treatment by 312.5 |iM sodium butyrate. Pattern of basal expression levels for 
all three SEAP reporter constructs were found to resemble that observed for LC978 
(Section 4.6.3) and hydroxyurea (Section 4.6.4) experiment. 
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Volume of DMRIE-C 
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Figure 4.1 Optimal Dose of DMRIE-C Reagent for K562 Transfection. 
pEGFP-Nl vector carrying an Enhancer Green Fluorescent Protein 
(EGFP) driven by a constitutive human cytomegalovirus (CMV) 
promoter was transiently transfected into K562 cells using different 
amount of DMRIE-C transfection reagent. Fluorescent micrographs 
were captured at hour post transfection. Transfection setup using 
8|al DMRIE-C reagent was arbitrarily found to be showing the highest 
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Figure 4.2 pSV-f-gal Transfection and p-Galactosidase Assay on K562 Cells. 
pSV-p-gal vector carrying an p-gal gene driven by SV40 early promoter 
and enhancer was transiently transfected into K562 cells. Mock 
transfection as using sfRPMI 1640 solely was set as negative control. 
Data was analyzed by one-way ANOVA followed by Tukey's multiple 
comparison test. Result showed that DMRIE-C only did not contribute 
to a significant difference to the negative control. The group transfected 
by pSV-p-gal showed a significant difference to the negative control 
with P < 0.001. 
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Figure 4.3 HbF Production by Dual-Vector Co-Transfected K562 Cells Upon 
LC978 Treatment. K562 cells transiently co-transfected by 
pSEAP2-Enhancer (OP), pl224yAP-SEAP2-YAE (-1224P), 
p754YAP-SEAP2-yAE (-754P) or p205yAP-SEAP2-yAE (-205P) 
together with pSV-|3-gal were treated by 3.125ng/ml LC978 at 24 '^' hour 
post transfection. At 3 . d a y post LC978 treatment, cell lysates were 
assayed for HbF production by HbF quantitation ELISA. Result 
showed that HbF expression levels of LC978-treated groups were 
significantly higher than that of their corresponding un-treated groups. 
0.001) 
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Figure 4.4 SEAP Expression by Dual-Vector Co-Transfected K562 Cells Upon 
LC978 Treatment. K562 cells transiently co-transfected by 
pSEAP2-Enhancer (OP), pl224yAP-SEAP2-yAE (-1224P), 
p754yAP-SEAP2-yAE (-754P) or p205丫AP-SEAP2-YAE (-205P) 
together with pSV-|3-gal were treated by 3.125ng/ml LC978 at 24*'' hour 
post transfection. At 3 . d a y post LC978 treatment, each group was 
quantified for SEAP activity by SEAP reporter assay. Result showed 
that there was no significant difference between treated and un-treated 
group for cells transfected with promoter-less construct. Cells groups 
that were transfected either by -1224, -754 or -205 promoter construct 
showed a significant decrease in SEAP activity upon LC978 treatment. 
( *** :P< 0.001) 
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Figure 4.5 Total Hemoglobin Production Induced by Hydroxyurea over a 
8-Day Period. 1 x lO* cell/ml K562 cells were treated with various 
concentrations of hydroxyurea. The total hemoglobin contents over an 
8-day experimental period were assayed by in vitro bioassay for 
hemoglobin, and the developed colour was measured at 600nm by 
SpectraMAX 250 microplate spectrophotometer. Data was normalized 
to percentage maximal response by GraphPad Prism® software and a 
sigmoidal dose-response curve was plotted. Percentage maximal 
response vs. hydroxyurea concentrations over an 8-day incubation 
period was presented above, with each error bar indicates the standard 
deviations of a group of triplicate. Hydroxyurea at 25)ig/ml was found 
to be inducing highest expression level of total hemoglobin. 
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Figure 4.6 HbF Production by Dual-Vector Co-Transfected K562 Cells Upon 
Hydroxyurea Treatment. K562 cells transiently co-transfected by 
pSEAP2-Enhancer (OP), pl224YAP-SEAP2-yAE (-1224P), 
p754yAP-SEAP2-YAE (-754P) or p205yAP-SEAP2-yAE (-205P) 
together with pSV-p-gal were treated by 25|ig/ml hydroxyurea at 24出 
hour post transfection. At 3.5^ day post hydroxyurea treatment, cell 
lysates were assayed for HbF production by HbF quantitation ELISA. 
Result showed that HbF expression levels of hydroxyurea-treated 
groups were significantly higher than that of their corresponding 
un-treated groups. (***: P < 0.001) 
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Figure 4.7 SEAP Expression by Dual-Vector Co-Transfected K562 Cells Upon 
Hydroxyurea Treatment. K562 cells transiently co-transfected by 
pSEAP2-Enhancer (OP), pl224YAP-SEAP2-yAE (-1224P), 
p754yAP-SEAP2-YAE (-754P) or p2057AP-SEAP2-YAE (-205P) 
together with pSV-P-gal were treated by 25|ig/ml hydroxyurea at 
hour post transfection. At day post hydroxyurea treatment, each 
group was quantified for SEAP activity by SEAP reporter assay. Result 
showed that there was no significant difference between treated and 
un-treated group for cells transfected with promoter-less or -1224 
promoter construct. Cells groups that were transfected either by -754 
or -205 promoter construct showed a significant decrease in SEAP 
activity upon hydroxyurea treatment. (*•*： P < 0.001) 
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Figure 4.8 Fetal Hemoglobin Production Induced by Sodium Butyrate over a 
6-Day Period. 1 x cell/ml K562 cells were treated with various 
concentrations of sodium butyrate. The fetal hemoglobin contents over 
a 6-day experimental period were assayed by HbF quantification 
ELISA, and the developed colour was measured at 650nm by 
SpectraMAX 250 microplate spectrophotometer. Data was normalized 
to percentage maximal response by GraphPad Prism® software and a 
sigmoidal dose-response curve was plotted. Percentage maximal 
response vs. sodium butyrate concentrations over an 6-day incubation 
period was presented above, with each error bar indicates the standard 
deviations of a group of triplicate. Sodium butyrate at 312.5|iM was 
found to be inducing highest expression level of fetal hemoglobin. 
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Figure 4.9 HbF Production by Dual-Vector Co-Transfected K562 Cells Upon 
Sodium Butyrate Treatment. K562 cells transiently co-transfected by 
pSEAP2-Enhancer (OP), pl224yAP-SEAP2-yAE (-1224P), 
p754YAP-SEAP2-yAE (-754P) or p205yAP-SEAP2-YAE (-205P) 
together with pSV-P-gal were treated by 312.5|iM sodium butyrate at 
24出 hour post transfection. At day post butyrate treatment, cell 
lysates were assayed for HbF production by HbF quantitation ELISA. 
Result showed that HbF expression levels of butyrate-treated groups 
were generally slightly higher than that of their corresponding 
un-treated groups. For transfected cells groups of promoter-less 
or -1224 promoter constructs, the difference was determined to be 
statistically not significant. For transfected cells groups of -754 or -205 
promoter constructs, the difference was determined to be statistically 
significant. (***: < 0.001) 
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Figure 4.10 SEAP Expression by Dual-Vector Co-Transfected K562 Cells Upon 
Sodium Butyrate Treatment. K562 cells transiently co-transfected by 
pSEAP2-Enhancer (OP), pl224YAP-SEAP2-yAE (-1224P), 
P754YAP-SEAP2-YAE (-754P) or p205yAP-SEAP2-yAE (-205P) 
together with pSV-f-gal were treated by 312.5nM sodium butyrate at 
24th hour post transfection. At day post butyrate treatment, each 
group was quantified for SEAP activity by SEAP reporter assay. Result 
showed that there was no significant difference between treated and 
un-treated group for cells transfected with promoter-less construct. 
Cells groups that were transfected either by -1224, -754 or -205 
promoter construct showed a significant increase in SEAP activity upon 
LC978 treatment. (***: P<0.001) 
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4.7 Discussion 
4.7.1 Theme Question to be Answered 
In this study, the main question asked was: Which part of the human A gamma globin 
gene promoter is responsible for LC978 induced reactivation? Thus, it came to 
design of the experiment: by linking different lengths of human A gamma globin 
gene promoter fragments to a reporter gene, the activity of each of them under 
influence of pharmaceutical induction by optimal dose of LC978 was investigated. In 
previous chapter, it has been described the construction of the promoter truncations, 
that SEAP reporter constructs driven by each of-1224, -754 and -205 human A 
gamma globin gene promoter were built. It was expected that, if a deletion removed 
important autonomous inhibitory element, the induction would result in an increased 
activity towards LC978. However, if the deletion removed positive regulatory 
element that is responsive to LC978, the induction change thereafter would be 
reduced. 
4.7.2 Optimal Dose of DMRIE-C Transfection Reagent on K562 Cell Line 
The first part of the study focused on determining optimal study protocol using the 
described strategy in Section 4.3, as well as studying the feasibility of using 
pSV-P-gal as normalization vector for variations of transfection efficiencies among 
different wells. From the result, it was determined that Sjil DMRIE-C transfection 
reagent was optimal to transient transfection of K562 cell line regarding transient 
expression of enhanced green fluorescent protein (EGFP). The pEGFP-Nl plasmid 
vector used for this experiment was driven by a constitutive human cytomegalovirus 
(CMV) promoter, in which the transcription of the EGFP gene would immediately 
begin after penetrating into cells. Therefore, the major determinant that gave rise to 
variation in EGFP expression was due to transfection efficiency, that is, number of 
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plasmid vector that can be transfected into the cells. On the other hand, intrinsic 
cytotoxic property of the cationic lipid based transfection reagent, however, may 
pose detrimental effect on expression of EGFP, by leading to restricted cell growth or 
hampered reporter expression. It was shown that DMRIE-C higher than 8|xl would 
result in slightly diminished EGFP expression, which was presumably due to 
cytotoxic effect that the cationic lipid based transfection reagent exerted onto the 
cells (Uchida et al., 2002). 
4.7.3 pSV-p-gal as an Internal Normalization Control 
pSV-P-gal was included in transfection experiment as internal normalization control 
for variations in transfection efficiencies between groups. Before study could 
proceed, investigation was performed to determine its expression on K562 cell line. 
It was determined that only the pSV-p-gal transfected group showed a significant 
increase in P-galactosidase activity compared to mock transfection negative control, 
and that transfection reagent-only mock control group did not show elevation in 
P-galactosidase activity compared to mock transfection negative control. This 
suggested that pSV-p-gal vector as well as p-galactosidase enzyme assay system was 
applicable to normalization of variations in transfection efficiencies between groups 
for transient transfection of K562 cell line (Lim & Chae, 1989). 
4.7.4 Responsive Element Mapping 
Experiment on promoter responsive element mapping was performed by transient 
transfection, followed by pharmaceutical induction on transiently transfected cells. 
Promoter-less pSEAP2-Enhancer was included as negative control. Activity of SEAP 
reporter was then assayed by SEAP reporter assay kit, where the SEAP activities 
were normalized to P-galactosidase activity. In each of the transfection-induction 
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groups, the cells were also collected for HbF quantitation by ELISA to investigate 
the change in HbF level induced by pharmaceutical agents. In this study, 
hydroxyurea and sodium butyrate were also included into the test system for 
comparisons. 
a) LC978-Induced Response 
All groups of transiently co-transfected K562 cells, when treated with 3.125ng/ml 
LC978, showed significant elevated level of fetal hemoglobin production compared 
to the co-transfected but untreated groups. The result suggested that K562 cells, 
though treated with DMRIE-C and incubated at high density during transfection, 
retained their potent gamma globin gene reactivation response towards LC978. When 
the supernatants were assayed for SEAP production, strikingly, it was found that all 
co-transfected carrying promoter-reporter constructs showed significant decreased of 
SEAP activity towards LC978 induction, which was completely opposite to what it 
was expected in early part of the discussion. Also, it was found that the extents of 
reduction in SEAP activity for -1224. -754 and -205 promoter constructs were 
roughly the same. 
b) Hydroxyurea-Induced Response 
Results obtained from hydroxyurea were similar to that of LC978. Prior to 
experiment, OBD of hydroxyurea on K562 cells were determined by in vitro 
bioassay for hemoglobin with procedures same as described in Section 2.4.1. The 
determined dose was 25|ig/ml. Upon co-transfection, K562 cells were then treated 
with 25|ig/ml hydoxyurea. HbF ELISA revealed that the transfected K562 cells also 
retained their gamma globin gene reactivation response towards hydoxyurea. And 
similarly, no induction of increased SEAP activity was found for hydroxyurea treated 
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groups. However, data showed that there was no difference between treated and 
untreated groups for -1224 promoter construct. But for -754 and -205 promoter 
constructs, the hydroxyurea treated groups showed diminished SEAP activity, 
with -205 promoter construct showing a comparatively greater extent of reduction. 
c) Sodium Butyrate-Induced Response 
Results from sodium butyrate represented another type of responsive profile. The 
OBD of sodium butyrate was determined to be 312.5|j.M by HbF quantitation ELISA. 
However, when cells were co-transfected and induced by the dose, HbF levels were 
only slightly elevated, with statistically significant difference only observed from 
two of the four co-transfection groups, with the remaining two groups showed no 
significant difference to their corresponding untreated controls. Surprisingly, the 
SEAP activity of butyrate induced groups were significantly elevated when 
compared to their untreated controls, with SEAP activity ratio between means of 
treated and untreated groups of approximately 5.1 for -1224, 4.3 for -754 and 3.4 
for -205 promoter constructs. This result was consistent with the study by 
McCaffrey's group, where they determined that butyrate was capable to induce 
human gamma globin gene -1091, -765 and -198 promoters respectively 
(McCaffrey et al” 1997). This implicated that the system used in this study can show 
inducible pattern once an appropriate induction was applied, and the negative results 
obtained from this study were unlikely due to intrinsic technical defect. 
4.7.5 LCR-Dependent Gamma Globin Gene Reactivation 
The decrease in SEAP activity for LC978-induced co-transfected K562 cells was 
proven not due to ineffectiveness of induction or interference of induction by 
transfection conditions, as suggested by positive regulation fetal hemoglobin 
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synthesis revealed by HbF ELISA. It was believed that the cellular mechanism that 
was required to switch on human A gamma globin gene expression existed upon 
LC978 induction, while the cellular response did not constitute to switching on of the 
promoter-reporter constructs on plasmid DNA. An explanation to this could be 
incomplete transcription apparatus formation on plasmid constructs upon LC978 
induction. Clearly, when endogenous gamma globin gene could be induced, the 
c/i,-acting DNA elements and trans-2iCimg protein factors that activate gamma globin 
gene promoter should co-exist in the beta-globin gene locus of transfected and 
LC978 induced cells. Under the circumstance, it was believed that SEAP gene on 
plasmid DNA and gamma globin gene in endogenous chromatin should share the 
same set of LC978 induced /ra«5-acting transcription factors. If the former could not 
transcribe at all, it is highly likely that cw-element was missing in the plasmid DNA. 
It was believed that the locus control region (LCR) of beta globin genes locus may be 
playing an important role in LC978-induced gamma globin gene expression, in 
which the promoter-reporter constructs that did not contain the LCR resulted in 
showing no inductive response towards LC978. Previous studies suggested that LCR 
serves as distal promoter for binding of transcriptional activators or mediators that 
regulate interactions between the LCR and the proximal promoter of each of the 
down stream globin genes which are important for transcription initiation of the 
genes (Orkin, 1995; Amrolia et al., 1997; Jane et al., 1992; Stamatoyannopoulos, 
1995). In fact, it was also reported that binding of transcription factors to LCR 
enhances high-level gene expression by interacting with proximal promoters to form 
enhanceosome through a flip-flop mechanism (Wijgerde et ah, 1995). These findings 
altogether suggested that, if the trans-sictmg factors that positively regulate gamma 
globin promoter activity require LCR to function properly, an absence of LCR might 
lead to abolishment of the promoter activity. This view was also implicated by 
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experimental data obtained from SEAP assay. Under induction by LC978, it was 
shown that all the SEAP and thus promoter activity from all transfected groups were 
decreased compared to the untreated basal controls, suggested that the transcription 
apparatus that formed for basal promoter activity was negatively affected by LC978 
treatment. Explanation to this could be the presence of binding of erythroid specific 
transcription factors, which blocked other non-specific basal transcription factors 
from interacting at close proximity to the promoters, and thus led to decreased 
LC978 induced promoter activity compared to basal promoter activity. 
As transiently transfected cells exhibited a similar response to hydroxyurea, that is, 
positive HbF regulation but negative SEAP regulation, it was believed that 
hydroxyurea might also require LCR for successful reactivation of gamma globin 
gene promoter. Though greatly similar, results suggested that hydroxyurea possess 
slightly different activity profile to LC978. Data showed that hydroxyurea induced 
promoter activity blockade occurred at -754 and -205 gamma globin gene promoter, 
while no difference between treated and untreated groups was observed for -1224 
promoter. This data implicated that hydroxyurea-induced subset of transcription 
factors may be different from that induced by LC978, by exhibiting different binding 
sites on gamma globin gene promoter. Previous study by Xing suggested that 
hydroxyurea induced gamma globin gene reactivation by exerting cytotoxicity onto 
K562 cells to accelerate erythroid regeneration, and produced premature terminally 
differentiated cells that express HbF, while no cell differentiation was detected for 
treatment by LC978 (Xing, 2003). This suggested that LC978 and hydroxyurea could 
be possible to possess two different mechanisms on gamma globin gene reactivation 
at the molecular level. 
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4.7.6 Induction of Gamma Globin by Histone Deacetylase Inhibitor 
The result given by sodium butyrate was in contrast to that given by LC978 and 
hydroxyurea, in which a significant high level of induction of SEAP activity was 
detected upon butyrate treatment. This could be due to differences in action 
mechanism of sodium butyrate to that of LC978 and hydroxyurea. As reported 
previously, butyric acid such as sodium butyrate can reactivate gamma globin gene 
production (Dover et al., 1992; Perrine & Faller, 1993; Zitnik et al., 1995). The 
mechanism involved, however, is not clearly understood. It was believed that 
butyrate mediates gamma globin gene reactivation mainly through two mechanisms, 
by inhibiting histone deacetylase and by modulating transcription factor bind 
specifically onto proximal promoter of gamma globin gene (McCaffrey et cd., 1997; 
Pace et al.’ 2000). Sodium butyrate inhibits histone deacetylase, which in turn 
maintain histone hyperacetylation that lead to altered chromatin structure and 
function and result in easier access by DNA binding proteins such as transcription 
factors (McCaffrey et al., 1997; Turner, 1991). Other studies also reported that 
sodium butyrate is actually capable of arousing specific transcription factors that 
bind to gamma globin gene proximal promoter, and butyrate-responsive element on 
the promoter was mapped (Pace et al.’ 2000). In fact, the result obtained in this study 
was found to resemble that obtained by Pace group, in which they showed that basal 
expression pattern of uninduced gamma globin promoter was highest at -730 
promoter, slightly lower at -201 and sudden drop at -1224 promoter. Pace mapped 
that butyrate responsive element was at -822 to -893, which was also implicated by 
the data obtained in this study, where the -1224 promoter showed a 5.1-fold increase 
in SEAP expression upon butyrate induction, which was the highest difference 
among the three constructs tested. 
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4.7.7 Basal SEAP Expression Levels of the Promoter-Reporter Constructs 
From all sets of SEAP reporter assay results including LC978 group (Figure 4.4), 
hydroxyurea group (Figure 4.7) and sodium butyrate group (Figure 4.10), it was 
observed that their basal SEAP expression patterns of the three promoter-reporter 
constructs were similar to each other. From all three groups of results, it was found 
that the truncation of gamma globin gene promoter from -754 to -205 only imposed 
a slight decrease of basal SEAP expression, while truncation of the promoter 
from -1224 to -754 caused a drastic increase in basal SEAP expression. This 
phenomenon implied that a potent negative regulatory element exists between -1224 
to -754 of the human gamma globin gene proximal promoter. It was hypothesized 
that there was an autonomous silencing element blocked the basal activity of the 
human gamma globin gene promoter, where the removal of the element increased the 
basal activity of the promoter. This finding shed light on mapping of functional 
element on human gamma globin gene proximal promoter, and proposed possible 
direction of investigations in the future. 
4.7.8 Summary 
Summarizing all these observations and previous studies, it was found that LC978 
may not possess histone deacetylase inhibition activity. Promoter dissection assay 
suggested that LC978 might be able to induce binding of some transcription factors 
onto gamma globin gene proximal promoter, while their identity and activity 
remained unknown. It was assumed that LCR is required to confer positive 
reactivation of gamma globin gene promoter towards LC978. 
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Chapter 5 General Discussion 
5.1 Overview 
LC978 has been proven a potent HbF inducer on K562 cell line, normal human 
erythroid progenitor cells and erythroid progenitor cells of beta-thalassemia patient. 
In vitro study determined that the efficacy of LC978 in inducing HbF production was 
2000-fold higher than that of hydroxyurea, with broader safety margin, suggested 
that LC978 is a potential drug candidate in treating beta-thalassemia (Xing, 2003). 
For a novel lead compound, much of its details were unknown. This project was 
pioneer study aimed at revealing promoter regulation induced by LC978 during 
gamma globin gene reactivation. Classic drugs that have been proven to induce HbF 
production such as hydroxyurea and sodium butyrate were included into this study, in 
which each of them represented a main group of HbF inducers categorized by their 
drug action mechanisms. Hydroxyurea represents cytotoxic inducers, which it 
induces HbF production by exerting cytotoxic stress on cells to accelerate erythroid 
regeneration and bring up premature terminally differentiated cells that retain 
transcriptional environment to support gamma globin synthesis. Sodium butyrate 
induces HbF production by maintaining histone hyperacetylation, such that to alter 
chromatin structure to allow easy access by transcription factors. Both drugs 
mechanisms suggested that they are non-specific inducers of gamma globin gene. 
From the experiments, it was shown that LC978 behaved similar action profile as 
hydroxyurea, while in contrast, LC978 induced gamma globin gene expression at a 
dosage without cytotoxic effect. Also, from study performed by Xing, it was shown 
that induction of HbF by LC978 does not lead to cell differentiation. Dr. Fung's 
laboratory unpublished data suggested that LC978 induced HbF production may be 
mediated via p38 mitogen activated protein (MAP) kinase, which was shown to be 
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same as hydroxyurea (Park et al., 2001). Altogether, these data suggested that LC978 
is a specific inducer of gamma globin gene preferable to hydroxyurea, which is a 
currently widely used FDA-approved drug. 
5.2 Further Study 
Though not directly answered to the theme question asked in the beginning of the 
project, the finding of this study provided hints on LC978-mediated gamma globin 
gene promoter regulation. First, it is postulated that the cw-acting element LCR may 
be involved in LC978-mediated gamma globin gene reactivation. Second, there may 
be recruitment of a subset of LC978-induced transcription factors to close proximity 
of the gamma globin gene promoter. These findings suggested the blueprint of 
further study. It is expected that, when LCR is restored into the promoter constructs 
used in this study, induction of reporter can be restored, and further study on 
mapping LC978-responsive elements can be conducted. Furthermore, the 
transcription factors that bind to the gamma globin promoter under LC978 induction 
can be identified by gel shift assay using promoter fragments. Identification of this 
subset of transcription factors can provide insights to linking the downstream 
transcription factors to upstream p38 MAP kinase mediator. On the other hand, the 
observation of negative promoter regulation at -754 to -1224bp of gamma globin 
gene promoter suggested the discovery of a novel potent regulatory element. 
Nevertheless, much of its details remained unknown. Most straightforward study 
could be to determine its tissue specificity in negative promoter regulation, to see if 
erythroid specific transcription factors are required for promoter repression. Future 
investigations could be focused on revealing its functional role in human globin 
genes switching. 
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It is believed that LC978, not only as a potent drug candidate, but also serves as tool 
for specific gamma globin gene reactivation, may enable precise investigation of 
molecular mechanisms governing globin genes regulations. 
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